Health Insurance (Pathology Services Table) Regulations 2004 (Cth)

Text

1 Name of Regulations [see Note 1]

2 Commencement

3 Health Insurance (Pathology Services Table) Regulations 2003 — repeal

4 Definitions

5 Pathology services table

1A Prescription of table

1 Interpretation of table

2 Precedence of items

3 Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request

4 Services to which rule 3 does not apply

5 Item taken to refer only to the first service of a particular kind

6 Certain items not to apply to a service referred by one pathology practitioner to another

7 Items not to be split

8 Creatinine ratios — Group P2 (Chemical)

9 Thyroid function testing

10 Meaning of serial examinations or cultures

11 Investigation for hepatitis serology

12 Tests in Group P4 (Immunology) relating to antibodies

13 Tests on biopsy material — Group P5 (Tissue pathology) and Group P6 (Cytology)

14 Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances

15 Application of an item in Group P11 (Specimen referred) to a service excludes certain other items

16 Circumstances in which an item in Group P11 (Specimen referred) does not apply

17 Abbreviations

18 Certain pathology services to be treated as 1 service

19 Hepatitis C viral RNA testing

20 Haemochromatosis testing

21 Serum B12 and red cell folate testing

22 Nutritional and toxicity metals testing

23 Antineutrophil cytoplasmic antibody tests

24 Satisfying requirements described in pathology service

25 Limitation on certain items

Health Insurance (Pathology Services Table) Regulations 2004

Statutory Rules 2004 No. 309 as amended

made under the

Health Insurance Act 1973

This compilation was prepared on 1 May 2005
taking into account amendments up to SLI 2005 No. 67

Prepared by the Office of Legislative Drafting and Publishing,
Attorney-General’s Department, Canberra

Contents

1 Name of Regulations [see Note 1] 3

2 Commencement 3

3 Health Insurance (Pathology Services Table) Regulations 2003 — repeal 3

4 Definitions 3

5 Pathology services table 4

Schedule 1 Table of pathology services 5

Part 1 Prescription of table 5

1A Prescription of table 5

Part 2 Rules of interpretation 5

1 Interpretation of table 5

2 Precedence of items 6

3 Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request 8

4 Services to which rule 3 does not apply 9

5 Item taken to refer only to the first service of a particular kind 10

6 Certain items not to apply to a service referred by one pathology practitioner to another 11

7 Items not to be split 13

8 Creatinine ratios — Group P2 (Chemical) 13

9 Thyroid function testing 13

10 Meaning of serial examinations or cultures 14

11 Investigation for hepatitis serology 14

12 Tests in Group P4 (Immunology) relating to antibodies 15

13 Tests on biopsy material — Group P5 (Tissue pathology) and Group P6 (Cytology) 15

14 Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances 16

15 Application of an item in Group P11 (Specimen referred) to a service excludes certain other items 19

16 Circumstances in which an item in Group P11 (Specimen referred) does not apply 19

17 Abbreviations 20

18 Certain pathology services to be treated as 1 service 20

19 Hepatitis C viral RNA testing 22

20 Haemochromatosis testing 22

21 Serum B12 and red cell folate testing 22

22 Nutritional and toxicity metals testing 22

23 Antineutrophil cytoplasmic antibody tests 23

24 Satisfying requirements described in pathology service 23

25 Limitation on certain items 24

Part 3 Services and fees 25

Part 4 Abbreviations 72

Part 5 Complexity levels for histopathology items 109

Notes 117

1 Name of Regulations [see Note 1]

These Regulations are the Health Insurance (Pathology Services Table) Regulations 2004.

2 Commencement

These Regulations commence on 1 November 2004.

3 Health Insurance (Pathology Services Table) Regulations 2003 — repeal

The following Statutory Rules are repealed:

· 2003 Nos. 256, 295, 300 and 360

· 2004 Nos. 66, 67, 238 and 268.

4 Definitions

In these Regulations:

Act means the Health Insurance Act 1973.

this table means these Regulations.

5 Pathology services table

The table of pathology services set out in Schedule 1 is prescribed for subsection 4A (1) of the Act.

Schedule 1 Table of pathology services

(regulation 5)

Part 1 Prescription of table

1A Prescription of table

For section 4A of the Act, these Regulations prescribe a table of pathology services that sets out:

(a) in Part 2 — rules for interpretation of the table; and

(b) in Part 3:

(i) items of pathology services; and

(ii) the amount of fees applicable for each item; and

Part 2 Rules of interpretation

1 Interpretation of table

(1) In this table:

item means:

(a) an item mentioned, by number, in column 1 of:

(i) Part 3; or

(ii) Part 3 of the diagnostic imaging services table; or

(iii) Part 3 of the general medical services table; and

(b) in a reference immediately followed by a number — the item so numbered.

patient episode means:

(a) a pathology service or pathology services (other than a pathology service to which paragraph (b) refers) provided for a single patient whose need for the service or services was determined under section 16A of the Act:

(i) on the same day; or

(ii) if more than 1 test is performed on the 1 specimen within 14 days — on the same or different days;

whether the services:

(iii) are requested by 1 or more practitioners; or

(iv) are described in a single item or in more than 1 item; or

(v) are rendered by 1 approved pathology practitioner or more than 1 approved pathology practitioner; or

(vi) are rendered on the same or different days; or

(b) a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relate to the service.

recognised pathologist means a medical practitioner recognised as a specialist in pathology by a determination under section 3D or subsection 61 (3) of the Act.

serial examinations means a series of examinations requested on 1 occasion whether or not:

(a) the materials are received on different days by the approved pathology practitioner; or

(b) the examinations or cultures were requested on 1 or more request forms by the treating practitioner.

(2) In these rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16A (6) of the Act applies.

(3) A reference to a Group in the table includes every item in the Group and a reference to a Subgroup in the table includes every item in the Subgroup.

2 Precedence of items

(1) If a service is described:

(a) in an item in general terms; and

(b) in another item in specific terms;

only the item that describes the service in specific terms applies to the service.

(2) Subject to subrule (3), if:

(a) subrule (1) does not apply; and

(b) a service is described in 2 or more items;

only the item that provides the lower or lowest fee for the service applies to the service.

(3) If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately.

Application of items 74990 and 74991

(4) Despite subrules (1), (2) and (3):

(a) if the pathology service described in item 74991 is provided to a person, either that item or item 74990, but not both those items, applies to the service; and

(b) if item 74990 or 74991 applies to a pathology service, the fee specified in that item applies in addition to the fee specified in any other item in this table that applies to the service.

(5) For items 74990 and 74991:

bulk-billed, in relation to a pathology service, means:

(a) a medicare benefit is payable to a person in respect of the service; and

(b) under an agreement entered into under section 20A of the Act:

(i) the person assigns to the practitioner by whom, or on whose behalf, the service is provided, his or her right to the payment of the medicare benefit; and

(ii) the practitioner accepts the assignment in full payment of his or her fee for the service provided.

Commonwealth concession card holder means a person who is a concessional beneficiary within the meaning given by subsection 84 (1) of the National Health Act 1953.

unreferred service means a pathology service that:

(a) is provided to a person by, or on behalf of, a medical practitioner, being a medical practitioner who is not a consultant physician, or specialist, in any speciality (other than a medical practitioner who is, for the purposes of the Act, both a general practitioner and a consultant physician, or specialist, in a particular speciality); and

(b) has not been referred to the medical practitioner by another medical practitioner or person with referring rights.

(6) For item 74991:

ASGC means the document titled Australian Standard Geographical Classification (ASGC) 2002, published by the Australian Bureau of Statistics, as in force on 1 July 2002.

practice location, in relation to the provision of a pathology service, means the place of practice in respect of which the practitioner by whom, or on whose behalf, the service is provided, has been allocated a provider number by the Commission.

regional, rural or remote area means an area classified as RRMAs 3-7 under the Rural, Remote and Metropolitan Areas Classification.

Rural, Remote and Metropolitan Areas Classification has the meaning given by subrule 3 (1) of Part 2 of Schedule 1 to the general medical services table.

SLA means a Statistical Local Area specified in the ASGC.

SSD means a Statistical Subdivision specified in the ASGC.

3 Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request

(1)In subrule (2), service includes assay, estimation and test.

(2)Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:

(a) the services are listed in the same item; and

(b) that item is not item 74990 or 74991; and

(c) the patient’s need for the services was determined under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than 1 day.

4 Services to which rule 3 does not apply

(1) Rule 3 does not apply to a pathology service described in item 65060, 65070, 65120, 65123, 65126, 65129, 65150, 65153, 65156, 66500, 66503, 66506, 66509, 66512, 66515, 66584 or 66800 if:

(a) the service is rendered in relation to 1 or more specimens taken on any of not more than 6 occasions in a period of 24 hours; and

(b) the service is rendered to an inpatient of a hospital; and

(c) in order to render the service, an approved pathology practitioner who is a recognised pathologist has to arrange for a member of the laboratory staff of the approved pathology authority concerned to undertake duties in respect of the service that are in addition to the usual duties of the staff member; and

(d) the account for the service is endorsed ‘Rule 3 Exemption’.

(2) Rule 3 does not apply to any of the following pathology services:

(a) estimation of prothrombin time (INR) for a patient undergoing anticoagulant therapy;

(b) quantitative estimation of lithium for a patient undergoing lithium therapy;

(c) a service described in item 65070 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;

(d) a service described in item 65070 in relation to
clozaril, ticlopidine hydrochloride, methotrexate, gold, sulphasalazine or penicillamine therapy of a patient;

(e) a service described in any of items 66500 to 66515, in relation to methotrexate or leflunomide therapy of a patient;

(f) quantitative estimation of urea, creatinine and electrolytes in relation to:

(i) cis-platinum or cyclosporin therapy of a patient; or

(ii) chronic renal failure of a patient being treated
in a dialysis program conducted by a recognised hospital;

(g) quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues;

if:

(h) under a request for a service, other than a request for a service described in paragraph (a), no more than 6 tests are requested; and

(i) the tests are performed within 6 months of the request; and

(j) the account for the service is endorsed ‘Rule 3 Exemption’.

5 Item taken to refer only to the first service of a particular kind

(1) For an item in Group P1 (Haematology):

(a) if pathology services of a kind referred to in item 65090 or 65093 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during the period; and

(b) if:

(i) tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out in relation to a patient episode; and

(ii) specimen material from the patient episode is stored; and

(iii) in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out on the stored material;

the later tests and the earlier tests are taken to be part of 1 patient episode.

(2) Items 65102 and 65108 apply only if a minimum of 6 units are issued for a patient’s care in any 1 day.

(3) For items 65099 and 65102:

compatibility tests by crossmatch means that, in addition to all the tests described in paragraphs (a) and (b) of the item, donor red cells from each unit must have been tested directly against the serum of the patient by 1 or more accepted crossmatching techniques.

6 Certain items not to apply to a service referred by one pathology practitioner to another

(1) In this rule:

designated pathology service means a pathology service in respect of tests relating to a single patient episode that are:

(a) tests of the kind described in item 66695; or

(b) tests of the kind described in item 66722; or

(d) tests of the kind described in item 66812; or

(e) tests of the kind described in item 69384.

(2) This rule applies in respect of a designated pathology service where:

(a) an approved pathology practitioner (practitioner A) in an approved pathology authority:

(i) has been requested to render the designated pathology service; and

(ii) is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more (but not all) of the tests included in the service; and

(iii) requests an approved pathology practitioner (practitioner B) in another approved pathology authority to render the test or tests that practitioner A is unable to render; and

(iv) renders each test included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and

(b) the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 66710, 66734, 66806, 66815 or 69399.

(3) If this rule applies in respect of a designated pathology service:

(a) item 66695, 66698, 66701, 66704, 66707, 66722, 66725, 66728, 66731, 66800, 66803, 66812, 69384, 69387, 69390, 69393 or 69396 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and

(b) where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii) — subject to subrule (4), the amount specified in item 66713, 66737, 66809, 66818 or 69402 (as the case requires) is payable for each test that the service comprises.

(4)For paragraph (3) (b), the maximum number of tests to which item 66713, 66737, 66809, 66818 or 69402 applies is:

(a) for item 66809:

3 – X; and

(b) for item 66818:

2 – X; and

6 – X;

where X is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made.

(5) Items in Group P10 (Patient episode initiation) do not apply to the second-mentioned approved pathology practitioner in subrule (2).

7 Items not to be split

Except as stated in rule 6, the amount specified in an item is payable only to 1 approved pathology practitioner in respect of a single patient episode.

8 Creatinine ratios — Group P2 (Chemical)

A pathology service mentioned in an item in Group P2 (Chemical) (except item 66500) that:

(a) involves the measurement of a substance in urine; and

(b) requires calculation of a substance/creatinine ratio;

is taken to include the measurement of creatinine necessary for the calculation.

9 Thyroid function testing

(1) For item 66719:

abnormal level of TSH means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level.

(2) Except where paragraph (a) of item 66719 is satisfied, the amount specified in the item is not payable for a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3).

(3) The written statement from the medical practitioner must indicate:

(a) that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66719; or

(b) that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or

10 Meaning of serial examinations or cultures

For an item in Group P3 (Microbiology):

(a) serial examinations or cultures means a series of examinations or cultures requested on 1 occasion whether or not:

(i) the materials are received on different days by the approved pathology practitioner; or

(ii) the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and

(b) if:

(i) tests are carried out in relation to a patient episode; and

(ii) specimen material from the patient episode is stored; and

(iii) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of 1 patient episode.

11 Investigation for hepatitis serology

(1) The fee applying in a single patient episode that includes any of items 69475, 69478 and 69481 is the fee specified for 1 only of those items.

(2) Item 69478 applies to a service in relation to which:

(a) a practitioner requests 2 tests for immune status or viral carriage; or

(b) the clinical notes indicate that the service is required for:

(i) pre-operative assessment; or

(ii) post-exposure to blood or other body fluids assessment; or

(iii) assessment before blood or tissue donation.

(3) Item 69481 applies to a service in relation to a patient who displays 1 or more of the characteristics of acute or chronic hepatitis.

12 Tests in Group P4 (Immunology) relating to antibodies

For items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:

(a) tests are carried out in relation to a patient episode; and

(b) specimen material from the patient episode is stored; and

(c) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of 1 patient episode.

13 Tests on biopsy material — Group P5 (Tissue pathology) and Group P6 (Cytology)

(1) For items in Group P5 (Tissue pathology):

biopsy material means all tissue (other than a bone marrow biopsy) received by an approved pathology practitioner:

(a) from a medical procedure, or group of medical procedures, performed on a patient at the same time; or

(b) after being expelled spontaneously from a patient.

cytology means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant but, in accordance with customary laboratory practice, does not include examination of a blood film and a bone marrow aspirate.

separately identified specimen means an individual specimen collected, identified so that it is clearly distinguished from any other specimen, and sent for testing by or on behalf of the treating practitioner responsible for the procedure in which the specimen was taken.

(2)For Groups P5 and P6 of the pathology services table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6.

(3) For subrule (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

(4)If more than 1 of the services mentioned in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 are performed in a single patient episode, only the fee for the item performed having the highest specified fee is applicable to the services.

(5) If more than 1 histopathological examinations are performed on separate specimens, of different complexity levels, from a single patient episode, only the fee for the examination having the highest specified fee is applicable to the examinations.

(6)In items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 a reference to a complexity level is a reference to the level given to a specimen type mentioned in Part 5 of this table.

(7) If:

(a) more than 1 of the services mentioned in items 72846, 72847 and 72848; or

(b) more than 1 of the services mentioned in items 73059, 73060 and 73061;

are performed in a single patient episode, only the fee for the item performed having the higher or highest specified fee applies to the services.

14 Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances

(1) For this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):

approved collection centre has the same meaning as in Part IIA of the Act.

institution means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:

(a) disadvantaged children; or

(b) juvenile offenders; or

(d) chronically ill psychiatric patients; or

(e) homeless persons; or

(f) unemployed persons; or

(g) persons suffering from alcoholism; or

(h) persons addicted to drugs; or

(i) physically or mentally handicapped persons;

but does not include:

(j) a hospital; or

(k) a residential care facility; or

(l) accommodation for aged persons that is attached to a residential care facility or situated within a residential care facility complex.

prescribed laboratory means a laboratory operated by:

(a) the Commonwealth; or

(b) an authority of the Commonwealth; or

(d) an authority of a State or internal Territory; or

(e) an Australian tertiary education institution.

residential care facility means a facility in which residential care, within the meaning of section 41-3 of the Aged Care Act 1997, is provided.

specimen collection centre has the same meaning as in Part IIA of the Act.

treating practitioner has the same meaning as in paragraph 16A (1) (a) of the Act.

(2) If a service described in an item in Group P10 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:

(a) the service is rendered upon a request made in the course of an out-patient service at a recognised hospital; or

(b) the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request is made; or

(d) a member of the staff of a recognised hospital, or a prescribed laboratory, participates in the service in the course of the member’s employment with the hospital or laboratory.

(3) An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A (7) of the Act applies.

(4) An item in Group P10 or P11 does not apply to a pathology service unless at least 1 item in Groups P1 to P8 also applies to the service.

(5) Subject to subrule (7), if 1 item in Group P10 applies to a patient episode, no other item in the Group applies to the patient episode.

(6) An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.

(7) If, in respect of the same patient episode:

(a) services referred to in 1 or more items in Group P5 and 1 or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; or

(b) services referred to in 1 or more items in Group P6 and 1 or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority;

the fee specified in the applicable item in Group P10 applies to both approved pathology practitioners.

(8) If more than one specimen is collected from a person on the same day for the provision of pathology services:

(a) in accordance with more than 1 request; and

(b) in or by a single approved pathology authority;

the fee specified in the applicable item in Group P10 applies once only to the services.

(9) The fee specified in item 73921 applies only once in respect of a single patient episode.

15 Application of an item in Group P11 (Specimen referred) to a service excludes certain other items

If item 73921 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology practitioner who claimed item 73921 in respect of the patient episode.

16 Circumstances in which an item in Group P11 (Specimen referred) does not apply

(1) An item in Group P11 does not apply to a referral if:

(a) a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and

(b) the approved pathology authority to which the referral is made is related to the referring approved pathology authority.

(2) An approved pathology authority is related to another approved pathology authority for subrule (1) if:

(a) both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or

(b) either of the approved pathology authorities is employed (including employed under contract) by the other; or

(c) both approved pathology authorities are corporations and are related corporations within the meaning of the Corporations Act 2001; or

(d) the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities); or

(e) both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or

(f) both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory.

(3) An item in Group P11 does not apply to a referral if the following common tests are referred either singly or in combination (except if the following items are referred in combination with other items not similarly specified): 65060, 65070, 65120, 66500, 66503, 66506, 66509, 66512, 66515, 66536, 66596, 69300, 69303, 69333 or 73527.

17 Abbreviations

(1) The abbreviations in Part 4 may be used to identify particular pathology services or groups of pathology services.

(2) The names of services or drugs not listed in Part 4 must be written in full.

18 Certain pathology services to be treated as 1 service

(1) In this rule:

general practitioner means a medical practitioner who:

(a) is not a consultant physician in any specialty; and

(b) is not a specialist in any specialty.

set of pathology services means a group of pathology services:

(a) that consists of services that are described in at least 4 different items; and

(b) all of which are requested in a single patient episode; and

(d) none of which is referred to:

(i) in item 66713, 66737, 66809, 66818, 69402, 69484, 73053 or 73055; or

(ii) in an item in Group P10 (Patient episode initiation), Group P11 (Specimen referred) or Group P12 (Management of bulk-billed services).

(2) If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule.

(3) If the fee specified in 1 item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set:

(a) the pathology service described in the first-mentioned item is to be treated as 1 pathology service; and

(b) either:

(i) the pathology service in the set that is described in the item that specifies the second-highest fee is to be treated as 1 pathology service; or

(ii) if 2 or more items that describe any of those services specify the second-highest fee — the pathology service described in the item that specifies the second-highest fee, and has the lowest item number, is to be treated as 1 pathology service; and

(c) the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service.

(4) If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set:

(a) the pathology service in the set that is described in the item that specifies the highest fee, and has the lowest item number, is to be treated as 1 pathology service; and

(b) the pathology service in the set that is described in the item that specifies the highest fee, and has the second-lowest item number, is to be treated as 1 pathology service; and

(c) the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service.

(5) If pathology services are to be treated as 1 pathology service under paragraph (3) (c) or (4) (c), the fee for the 1 pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the 1 pathology service.

19 Hepatitis C viral RNA testing

For item 69444:

Hepatitis C sero-positive, for a patient, means 2 different assays of Hepatitis C antibodies are positive.

serological status is uncertain, for a patient, means any result where 2 different assays of Hepatitis C antibodies are inconclusive.

20 Haemochromatosis testing

For item 66794:

elevated serum ferritin, for a patient, means a level of ferritin above the normal reference range in respect of the particular method of assay used to determine the level.

21 Serum B12 and red cell folate testing

(1) Items 66599 and 66602 do not apply to more than 3 patient episodes that include a service described in item 66599 or 66602, or any combination of those items, in a 12 month period.

(2) Item 66599 does not apply to a service described in that item if the service was provided as part of the same patient episode as a service described in item 66602.

22 Nutritional and toxicity metals testing

(1) For this rule:

metal toxicity testing group means items 66672 and 66673.

nutritional metals testing group means items 66669 and 66670.

(2) An item in the nutritional metals testing group or the metal toxicity testing group does not apply in relation to a service performed if medicare benefits are paid or payable for tests that are performed for the same patient in 3 patient episodes requested within 6 months before the request for that service, under any of:

(a) that item; or

(b) the other item in the same group; or

23 Antineutrophil cytoplasmic antibody tests

For subsection 16A (3) of the Act, a request for an antineutrophil cytoplasmic antibody immunofluorescence test is taken to include a request for an antineutrophil proteinase 3 antibody test and an antimyeloperoxidase antibody test if:

(a) the immunofluorescence test performed as a result of the request is abnormal; or

(b) a previous immunofluorescence test was abnormal; or

24 Satisfying requirements described in pathology service

Unless the contrary intention appears, a requirement contained in the description of a pathology service in Part 3 is satisfied if:

(a) in the case of a requirement for information, the information:

(i) is included in the request for the service; or

(ii) was supplied in writing on an earlier occasion to the approved pathology authority that rendered the service, and has been kept by the approved pathology authority; or

(b) in the case of a requirement for laboratory test results, the results are:

(i) included in the request for the service; or

(ii) obtained from another laboratory test performed in the same patient episode; or

(iii) included in results from an earlier laboratory test that have been kept by the approved pathology authority.

25 Limitation on certain items

(1) For any particular patient, items 66539, 69442, 71075, 71127, 71135 or 71137 are applicable not more than twice in a 12 month period.

(2) For any particular patient, item 66626 is applicable not more than 36 times in a 12 month period.

(3) For any particular patient, items 66655, 66659, 69443 or 69444 are applicable not more than once in a 12 month period.

(4) For any particular patient, item 66750 is applicable not more than once in a pregnancy.

(5) For any particular patient, item 69336 is applicable not more than once in each period of 7 days.

(6) For any particular patient, items 69445, 71079, or 73523 are applicable not more than 4 times in a 12 month period.

(7) For any particular patient, item 71077 is applicable not more than 6 times in a 12 month period.

Part 3 Services and fees

Item	Pathology service	Fee ($)
Group P1 — Haematology
65060	Haemoglobin, erythrocyte sedimentation rate, blood viscosity — 1 or more tests	7.95
65066	Examination of: (a) a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or (b) a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha-naphthyl acetate esterase or chloroacetate esterase; or (c) a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or (d) a urinary sediment for haemosiderin; including a service described in item 65072	10.55
65070	Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and manual or instrument generated differential count (not being a service where haemoglobin only is requested) — 1 or more instrument-generated set of results from a single sample and (if performed): (a) a morphological assessment of a blood film; and (b) any service in item 65060 or 65072	17.20
65072	Examination for reticulocytes including a reticulocyte count by any method — 1 or more tests

65075		Haemolysis or metabolic enzymes — assessment by 1 or more of the following tests: (a) erythrocyte autohaemolysis test; (b) erythrocyte osmotic fragility test; (c) sugar water test; (d) G-6-P D (qualitative or quantitative) test; (e) pyruvate kinase (qualitative or quantitative) test; (f) acid haemolysis test; (g) quantitation of muramidase in serum or urine; (h) Donath Landsteiner antibody test; (i) other erythrocyte metabolic enzyme tests	52.90
65078		Tests for the diagnosis of thalassaemia when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 2 of: (a) examination for HbH; or (b) quantitation of HbA2; or (c) quantitation of HbF; including (if performed) any service described in item 65060 or 65070	91.75
65081		Tests for the investigation of haemoglobinopathy (including S, C, D, E), other than thalassaemia, when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 1 of: (a) heat denaturation test; or (b) isopropanol precipitation test; or (c) tests for the presence of haemoglobin S; or (d) quantitation of any haemoglobin fraction (including S, C, D, E); including (if performed) any service described in item 65060, 65070 or 65078	98.25
65084		Bone marrow trephine biopsy — histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed): (a) special stains or immunohistochemical techniques (if any); and (b) any test described in item 65060, 65066 or 65070	168.75
65087		Bone marrow — examination of aspirated material (including clot sections where necessary), including (if performed): (a) special stains or immunohistochemical techniques (if any); and (b) any test described in item 65060, 65066 or 65070	84.55
65090		Blood grouping (including back-grouping if performed) — ABO and Rh (D antigen)	11.25
65093		Blood grouping — Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system — 1 or more systems, including item 65090 (if performed)	22.35
65096		Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including: (a) identification and quantitation of any antibodies detected; and (b) (if performed) any test described in item 65060 or 65070	41.65
65099		Compatibility tests by crossmatch — all tests performed on any one day for up to 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies, and if necessary identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090 or 65096 (Item is subject to rule 5)	113.40
65102		Compatibility tests by crossmatch — all tests performed on any one day in excess of 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies, and if necessary identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105 (Item is subject to rule 5)	170.10
65105		Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion — all tests performed on any one day for up to 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090 or 65096 (Item is subject to rule 5)	113.40
65108		Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion — all tests performed on any one day in excess of 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105 (Item is subject to rule 5)	170.10
65111		Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)	23.60
65114		1 or more of the following tests: (a) direct Coombs (antiglobulin) test; (b) qualitative or quantitative test for cold agglutinins or heterophil antibodies	9.25
65117		1 or more of the following tests: (a) spectroscopic examination of blood for chemically altered haemoglobins; (b) detection of methaemalbumin (Schumm’s test)	20.60
65120		Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or 1 of fibrinogen degradation products, fibrin monomer or D-dimer — 1 test	14.05
65123		2 tests described in item 65120	20.60
65126		3 tests described in item 65120	28.35
65129		4 or more tests described in item 65120	36.10
65132		Test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency, lupus anticoagulant, activated protein C resistance, if the request for the test specifically identifies that the patient has a history of venous thromboembolism — quantitation by 1 or more techniques — 1 test	25.75
65133		2 tests described in item 65132	49.50
65134		3 tests described in item 65132	73.20
65135		4 tests described in item 65132	96.90
65136		5 tests described in item 65132	120.65
65137		Test for the presence of lupus anticoagulant, not being a service connected with a service to which item 65132, 65133, 65134, 65135 or 65136 applies	25.75
65142		Confirmation or clarification of an abnormal or indeterminate result of a test mentioned in item 65132, by testing a specimen collected on a different day — 1 or more tests	25.75
65144		Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances; or heparin, low molecular weight heparins, heparinoid or other drugs — 1 or more tests	57.55
65147		Quantitation of anti-Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid — 1 test	38.55
65150		Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay — 1 test	72.15
65153		2 tests described in item 65150	144.35
65156		3 or more tests described in item 65150	216.50
65159		Quantitation of circulating coagulation factor inhibitors by Bethesda assay — 1 test	72.15
65162		Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test)	10.55
65165		Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell antigens using flow cytometric methods including (if performed) any test described in item 65070 or 65162	35.05
65168		Characterisation of the genotype of a patient for factor V Leiden gene mutation, or detection of other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism — 1 or more tests	37.10
65171		Test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency or activated protein C resistance in a first degree relative of a person who has a proven deficiency mentioned in this item — 1 or more tests	25.75
65174		Characterisation of the genotype of a person who is a first degree relative of a person who has been proven to have 1 or more abnormal genotypes under item 65168 — 1 or more tests	37.10
65200		Characterisation of gene rearrangement by nucleic acid amplification in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia; each test to a maximum of 4 tests in a 12 month period	235.00
Group P2 — Chemical
66500		Quantitation in serum, plasma, urine or other body fluid (except amniotic fluid), by any method, except reagent tablet or reagent strip, (with or without reflectance meter) of acetoacetate, acid phosphatase, alanine aminotransferase, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, beta-hydroxybutyrate, bicarbonate, bilirubin (total), bilirubin (any fractions), C-reactive protein, calcium (total or corrected for albumin), chloride, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, pyruvate, sodium, total cholesterol, total protein, triglycerides, urate or urea — 1 test	9.75
66503		2 tests described in item 66500	11.75
66506		3 tests described in item 66500	13.75
66509		4 tests described in item 66500	15.75
66512		5 tests described in item 66500	17.80
66515		6 or more tests described in item 66500	19.80
66518		Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood — tests performed on only 1 specimen in a 24 hour period	20.40
66519		Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood — tests performed on 2 or more specimens in a 24 hour period	40.85
66536		Quantitation of HDL cholesterol	11.25
66539		Electrophoresis of serum for demonstration of lipoprotein subclasses: (a) if the cholesterol is >6.5 mmol/L and triglyceride >4.0 mmol/L; or (b) in the diagnosis of types III and IV hyperlipidaemia (Item is subject to rule 25)	31.15
66542		Oral glucose tolerance test for the diagnosis of diabetes mellitus, that includes: (a) administration of glucose; and (b) at least 2 measurements of blood glucose; and (c) (if performed) any test described in item 66695	19.30
66545		Oral glucose challenge test in pregnancy for the detection of gestational diabetes that includes: (a) administration of glucose; and (b) 1 or 2 measurements of blood glucose; and (c) (if performed) any test in item 66695	16.10
66548		Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes: (a) administration of glucose; and (b) at least 3 measurements of blood glucose; and (c) (if performed) any test in item 66695	20.30
66551		Quantitation of glycosylated haemoglobin performed in the management of established diabetes — each test to a maximum of 4 tests in a 12 month period	17.10
66554		Quantitation of glycosylated haemoglobin performed in the management of pre-existing diabetes where the patient is pregnant — each test to a maximum of 6 tests in a 12 month period which includes the whole pregnancy, including a service in item 66551 (if performed)	17.10
66557		Quantitation of fructosamine performed in the management of established diabetes — each test to a maximum of 4 tests in a 12 month period	9.85
66560		Microalbumin — quantitation in urine	20.50
66563		Osmolality, estimation by osmometer, in serum or in urine — 1 or more tests	25.10
66566		Quantitation of: (a) blood gases (including pO₂, oxygen saturation and pCO₂); and (b) bicarbonate and pH; including any other measurement (eg haemoglobin, potassium or ionised calcium) or calculation performed on the same specimen — 1 or more tests on 1 specimen	34.30
66569		Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed on any 1 day	43.35
66572		Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed on any 1 day	52.45
66575		Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed on any 1 day	61.50
66578		Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed on any 1 day	70.55
66581		Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed on any 1 day	79.65
66584		Quantitation of ionised calcium (except if performed as part of item 66566) — 1 test	9.85
66587		Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least 1 blood specimen	48.35
66590		Calculus, analysis of 1 or more	31.15
66593		Ferritin — quantitation, except if requested as part of iron studies	18.35
66596		Iron studies, consisting of quantitation of: (a) serum iron; and (b) transferrin or iron binding capacity; and (c) ferritin	33.10
66599		Serum B12 or red cell folate and, if required, serum folate (Item is subject to rule 21)	24.05
66602		Serum B12 and red cell folate and, if required, serum folate (Item is subject to rule 21)	43.75
66605		Vitamins — quantitation of vitamins A, B1, B2, B3, B6, C and E in blood, urine or other body fluid — 1 or more tests within a 6 month period	31.15
66608		Vitamin D or D fractions — 1 or more tests	43.00
66623		All qualitative and quantitative tests on blood, urine or other body fluid for: (a) a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or (b) ingested or absorbed toxic chemicals; including a service described in item 66800, 66803, 66806, 66812 or 66815 (if performed), but excluding: (c) the surveillance of sports people and athletes for performance improving substances; and (d) the monitoring of patients participating in a drug abuse treatment program	42.25
66626		Detection or quantitation or both of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient participating in a drug abuse treatment program, including all tests on blood, urine or other body fluid, not including: (a) the surveillance of sports people and athletes for performance improving substances; and (b) the detection of nicotine and metabolites in smoking withdrawal programs (Item is subject to rule 25)	24.55
66629		Beta-2-microglobulin — quantitation in serum, urine or other body fluids — 1 or more tests	20.50
66632		Caeruloplasmin, haptoglobins, or prealbumin — quantitation in serum, urine or other body fluids — 1 or more tests	20.50
66635		Alpha-1-antitrypsin — quantitation in serum, urine or other body fluid — 1 or more tests	20.50
66638		Isoelectric focussing or similar methods for determination of alpha-1-antitrypsin phenotype in serum — 1 or more tests	29.70
66641		Electrophoresis of serum or other body fluid to demonstrate: (a) the isoenzymes of lactate dehydrogenase; or (b) the isoenzymes of alkaline phosphatase; including the preliminary quantitation of total relevant enzyme activity — 1 or more tests	29.70
66644		C-1 esterase inhibitor — quantitation	20.50
66647		C-1 esterase inhibitor — functional assay	45.90
66650		Alpha-fetoprotein, CA-15.3 antigen (CA15.3), CA-19.9 antigen (CA19.9), CA-125 antigen (C125), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), mammary serum antigen (MSA), thyroglobulin in serum or other body fluid, in the monitoring of malignancy or in the detection or monitoring of gestational trophoblastic disease or a hepatic or germ cell tumour — quantitation — 1 test	24.75
66653		2 or more tests described in item 66650	45.35
66655		Prostate specific antigen (PSA) quantitation (Item is subject to rule 25)	20.50
66656		Prostate specific antigen (PSA) quantitation in the monitoring of previously diagnosed prostatic disease (including a test to which item 66655 applies)	20.50
66659		Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies in the equivocal range of the particular method of assay used to determine the level (Item is subject to rule 25)	37.80
66662		Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast — 1 or more tests	81.35
66665		Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period — each test	31.15
66667		Quantitation of serum zinc in a patient receiving intravenous alimentation — each test	31.15
66669		Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid or tissue — 1 test (Item is subject to rule 22)	31.15
66670		Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid or tissue — 2 or more tests in relation to the same patient (Item is subject to rule 22)	53.35
66671		Quantitation of serum aluminium in a patient in a renal dialysis program — each test	37.55
66672		Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue — 1 test (Item is subject to rule 22)	31.15
66673		Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue — 2 or more tests in relation to the same patient (Item is subject to rule 22)	53.35
66674		Quantitation of: (a) faecal fat; or (b) breath hydrogen in response to loading with disaccharides; 1 or more tests within a 28 day period	40.65
66677		Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old	11.35
66680		Quantitation of disaccharidases and other enzymes in intestinal tissue — 1 or more tests	75.75
66683		Enzymes — quantitation in solid tissue or tissues other than blood elements or intestinal tissue — 1 or more tests	75.75
66686		Performance of 1 or more of the following procedures: (a) growth hormone suppression by glucose loading; (b) growth hormone stimulation by exercise; (c) dexamethasone suppression test; (d) sweat collection by iontophoresis for chloride analysis; (e) pharmacological stimulation of growth hormone	51.55
66689		Personal performance by a recognised pathologist of 1 of the following procedures: (a) gonadotrophin releasing hormone stimulation test; (b) synacthen stimulation test; (c) glucagon stimulation test with C-peptide measurement; (d) pentagastrin or calcium stimulation of thyrocalcitonin release; (e) secretin or calcium stimulation of gastrin release; (f) insulin hypoglycaemia; (g) arginine infusion; (h) thyrotrophin releasing hormone (TRH) test	82.50
66692		Personal performance by a recognised pathologist of 2 or more tests described in item 66689	144.35
66695		Quantitation in blood or urine of hormones and hormone binding proteins — ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF –1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone) — 1 test	30.70
66698		2 tests described in item 66695 (Item is subject to rule 6)	43.80
66701		3 tests described in item 66695 (Item is subject to rule 6)	57.20
66704		4 tests described in item 66695 (Item is subject to rule 6)	70.60
66707		5 tests described in item 66695 (Item is subject to rule 6)	84.05
66710		6 or more tests described in item 66695 (Item is subject to rule 6)	97.45
66713		Tests described in item 66695, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 5 tests (Item is subject to rule 6)	13.40
66716		TSH quantitation	25.45
66719		Thyroid function tests (comprising the service described in item 66716 and 1 or more of the following tests — estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) for a patient, if at least 1 of the following conditions is satisfied: (a) the patient has an abnormal level of TSH;	35.45
(b) the tests are performed: (i) for the purpose of monitoring thyroid disease in the patient; or (ii) to investigate the sick euthyroid syndrome if the patient is an admitted patient; or (iii) to investigate dementia or psychiatric illness of the patient; or (iv) to investigate amenorrhoea or infertility of the patient; (c) the medical practitioner who requested the tests suspects the patient has a pituitary dysfunction; (d) the patient is on drugs that interfere with thyroid hormone metabolism or function (Item is subject to rule 9)
66722		TSH quantitation described in item 66716 and 1 test described in item 66695 (Item is subject to rule 6)	38.55
66725		TSH quantitation described in item 66716 and 2 tests described in item 66695 (Item is subject to rule 6)	51.95
66728		TSH quantitation described in item 66716 and 3 tests described in item 66695 (Item is subject to rule 6)	65.35
66731		TSH quantitation described in item 66716 and 4 tests described in item 66695 (Item is subject to rule 6)	78.75
66734		TSH quantitation described in item 66716 and 5 tests described in item 66695 (Item is subject to rule 6)	92.15
66737		Tests described in items 66716 and 66695, if rendered under a request mentioned in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 5 tests (Item is subject to rule 6)	13.40
66743		Quantitation of alpha-fetoprotein in serum or other body fluids during pregnancy except if requested as part of item 66750 or 66751	20.50
66749		Amniotic fluid, spectrophotometric examination of, and quantitation of: (a) lecithin/sphingomyelin ratio; or (b) palmitic acid, phosphatidylglycerol or lamellar body phospholipid; or (c) bilirubin, including correction for haemoglobin; 1 or more tests	33.50
66750	Quantitation, in pregnancy, of any 2 of the following to detect foetal abnormality: (a) total human chorionic gonadotrophin (total HCG); (b) free alpha human chorionic gonadotrophin (free alpha HCG); (c) free beta human chorionic gonadotrophin (free beta HCG); (d) pregnancy associated plasma protein A (PAPP-A);		40.45
(e) unconjugated oestriol (uE₃); (f) alpha-fetoprotein (AFP); including (if performed) a service described in item 73527 or 73529 (Item is subject to rule 25)
66751	Quantitation, in pregnancy, of any 3 or more tests described in item 66750		56.20
66752		Quantitation of citrate, oxalate, total free fatty acids or amino acids including cysteine, homocysteine, cystine and hydroxyproline (except if performed as part of item 66773 or 66776) — 1 test	25.10
66755		2 or more tests described in item 66752	39.50
66758		Quantitation of angiotensin converting enzyme, or cholinesterase — 1 or more tests	25.10
66761		Test for reducing substances in faeces by any method (except reagent strip or dipstick)	13.40
66764		Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by: (a) an immunological method; and (b) a chemical method (except reagent strip or dip stick); with a maximum of 3 examinations on specimens collected on separate days in a 28 day period — 1 examination by both methods	9.05
66767		2 examinations by both methods described in item 66764 performed on separately collected and identified specimens	18.15
66770		3 examinations by both methods described in item 66764 performed on separately collected and identified specimens	27.20
66773		Quantitation of products of collagen breakdown for the monitoring of patients with proven low bone mineral density, and if performed, a service described in item 66752 — 1 or more tests	25.10
66776		Quantitation of products of collagen breakdown for the monitoring of patients with metabolic bone disease or Paget’s disease of bone, and if performed, a service described in item 66752 — 1 or more tests	25.10
66779		Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin — quantitation — 1 or more tests	40.65
66782		Porphyrins or porphyrins precursors — detection in plasma, red cells, urine or faeces — 1 or more tests	13.40
66785		Porphyrins or porphyrins precursors — quantitation in plasma, red cells, urine or faeces — 1 test	40.65
66788		Porphyrins or porphyrins precursors — quantitation in plasma, red cells, urine or faeces — 2 or more tests	67.00
66791		Porphyrin biosynthetic enzymes — measurement of activity in blood cells or other tissues — 1 or more tests	75.75
66794		Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis (Item is subject to rule 20)	37.10
66800		Quantitation in blood, urine or other body fluid by any method (except reagent tablet or reagent strip) of any of the following used therapeutically by the patient from whom the specimen was taken: amikacin, carbamazepine, digoxin, disopyramide, ethanol, ethosuximide, gentamicin, lignocaine, lithium, netilmicin, paracetamol, phenobarbitone, phenytoin, primidone, procainamide, quinidine, salicylate, theophylline, tobramycin, valproate or vancomycin — 1 test (Item is subject to rule 6)	18.45
66803		2 tests described in item 66800 (Item is subject to rule 6)	31.05
66806		3 tests described in item 66800 (Item is subject to rule 6)	43.60
66809		Tests described in item 66800, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 2 tests	12.60
66812		Quantitation, not elsewhere described in this table by any method or methods, in blood, urine or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken — 1 test (Item is subject to rule 6)	35.45
66815		2 tests described in item 66812 (Item is subject to rule 6)	60.60
66818		Tests described in item 66812, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 1 test (Item is subject to rule 6)	25.15
Group P3 — Microbiology
69300		Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including: (a) differential cell count (if performed); or (b) examination for dermatophytes; or (c) dark ground illumination; or (d) stained preparation or preparations using any relevant stain or stains; 1 or more tests	12.60
69303		Culture and (if performed) microscopy to detect pathogenic micro-organisms (including fungi but excluding viruses) from nasal swabs, throat swabs, eye swabs and ear swabs (except swabs taken for epidemiological surveillance), including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) the detection of antigens not elsewhere described in this table; or (c) a service described in item 69300; specimens from 1 or more sites	22.15
69306		Microscopy and culture to detect pathogenic micro-organisms (including fungi but excluding viruses) from skin or other superficial sites, including (if performed): (a) the detection of antigens not elsewhere specified in this table; or (b) pathogen identification and antibiotic susceptibility testing; or (c) a service described in items 69300, 69303, 69312, 69318 and 73810; 1 or more tests on 1 or more specimens	34.00
69309		Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease, from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed): (a) the detection of antigens not elsewhere specified in this table; or (b) a service described in items 69300, 69303, 69306, 69312, 69318 and 73810; 1 or more tests on 1 or more specimens	48.45
69312		Microscopy and culture to detect pathogenic micro-organisms (including fungi but excluding viruses) from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed): (a) the detection of antigens not elsewhere specified in this table; or (b) pathogen identification and antibiotic susceptibility testing; or (c) a service described in items 69300, 69303, 69306 and 69318; 1 or more tests on 1 or more specimens	34.00
69315		Microscopy and culture to detect pathogenic micro-organisms and the detection of chlamydia from urethra, vagina, cervix or rectum and including (if performed): (a) the detection of microbial antigens; or (b) pathogen identification and antibiotic susceptibility testing; or (c) a service described in item 69300, 69303, 69306, 69312, 69318, 69363, 69369, 69370, 69372, 69375 or 73810; 1 or more tests on 1 or more specimens	62.70
69318		Microscopy and culture to detect pathogenic micro-organisms (including fungi but excluding viruses) from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed): (a) the detection of antigens (from any type of specimen) not elsewhere specified in this table, including item 69372; or (b) pathogen identification and antibiotic susceptibility testing; or	34.00
(c) a service described in items 69300, 69303, 69306 and 69312; 1 or more tests on 1 or more specimens
69321		Microscopy and culture of post-operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic cultures and the use of different culture media, and including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) the detection of antigens not elsewhere specified in this table; or (c) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites	48.45
69324		Microscopy (with appropriate stains) and culture for mycobacteria — 1 specimen of sputum, urine or other body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service mentioned in item 69300	43.30
69327		Microscopy (with appropriate stains) and culture for mycobacteria — 2 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service described in item 69300	85.55
69330		Microscopy (with appropriate stains) and culture for mycobacteria — 3 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service described in item 69300	128.85
69333		Urine examination (including serial examination) by any means other than simple culture by dip slide, including: (a) cell count; and (b) culture; and (c) colony count; and (d) (if performed) identification of cultured pathogens; and (e) (if performed) examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts	20.70
69336	Microscopy of faeces for ova, cysts and parasites, that includes the use of: (a) a concentration technique; and (b) fixed stains or antigen detection for cryptosporidia and giardia; and includes a service mentioned in item 69300 (if performed) (Item is subject to rule 25)		33.65
69339	Microscopy of faeces for ova, cysts and parasites using concentration techniques examined after examination described in item 69336 performed on a separately collected and identified specimen collected within 7 days of the examination described in item 69336 — not more than 1 examination in a 7 day period		19.25
69345	Culture and (if performed) microscopy without concentration techniques of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed): (a) pathogen identification and antibiotic susceptibility testing; and (b) the detection of clostridial toxins; and (c) a service described in item 69300 Not more than 1 examination in a 7 day period		53.25
69354		Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed): (a) identification of any cultured pathogen; and (b) necessary antibiotic susceptibility testing; to a maximum of 3 sets of cultures — 1 set of cultures	30.95
69357		2 sets of cultures described in item 69354	61.85
69360		3 sets of cultures described in item 69354	92.80
69363		Detection of Clostridium difficile or Clostridium difficile toxin (except if a service described in item 69345, 69369, 69370, 69372, 69373 or 69375 has been performed) — 1 or more tests	28.85
69369		Detection of chlamydia by any method in specimens from 1 or more sites	28.85
69370		Detection of chlamydia by any method and Neisseria gonorrhoeae by nucleic acid amplification techniques in specimens from 1 or more sites	36.10
69372		Detection of microbial antigens or nucleic acids (not elsewhere described in this table) — 1 or more tests	28.85
69373		Detection of a virus or microbial antigen or nucleic acid from a respiratory tract specimen — 1 test	28.85
69374		2 or more tests described in item 69373	36.10
69375		Examination for Herpes simplex virus, varicella zoster virus or cytomegalovirus by culture or by detection of microbial antigen or nucleic acid, including a service described in item 69363, 69369, 69370, 69372 or 69373 (if performed) — 1 test	28.85
69376		2 or more tests described in item 69375	36.10
69378		Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero-positive patient not on antiretroviral therapy — 1 or more tests on 1 or more specimens	181.45
69381		Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero-positive patient on antiretroviral therapy — 1 or more tests on 1 or more specimens	181.45
69382		Quantitation of HIV viral RNA load in cerebrospinal fluid in a HIV sero-positive patient — 1 or more tests on 1 or more specimens	181.45
69384		Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in this table — 1 test (Item is subject to rule 6)	15.75
69387		2 tests described in item 69384 (Item is subject to rule 6)	28.85
69390		3 tests described in item 69384 (Item is subject to rule 6)	43.30
69393		4 tests described in item 69384 (Item is subject to rule 6)	57.75
69396		5 tests described in item 69384 (Item is subject to rule 6)	72.15
69399		6 or more tests described in item 69384	86.60
69402		Tests described in item 69384, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 5 tests (Item is subject to rule 6)	14.45
69405		Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of 1 of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and (b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481	15.75
69408		Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of 2 of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and (b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481	28.00
69411		Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of 3 of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and (b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481	39.35
69413		Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of all of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and (b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481	50.65
69442		Quantitation of HCV RNA load in plasma or serum in: (a) the pre-treatment evaluation, of a patient with chronic HCV hepatitis, for antiviral therapy; or (b) the assessment of efficacy of antiviral therapy for such a patient; if the test is requested by, or on the advice of, the specialist or consultant physician who manages the treatment of the patient (including a service described in item 69444 or 69445) (Item is subject to rule 25)	181.45
69443		Nucleic acid amplification and determination of hepatitis C virus (HCV) genotype if: (a) the patient is HCV RNA positive and is being evaluated for antiviral therapy of chronic HCV hepatitis; and (b) the request for the test is made by, or on the advice of, the specialist or consultant physician managing the treatment of the patient	206.20
(Item is subject to rule 25)
69444		Detection of Hepatitis C viral RNA if at least 1 of the following criteria is satisfied: (a) the patient is Hepatitis C sero-positive; (b) the patient’s serological status is uncertain after testing; (c) the test is performed for the purpose of: (i) determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; or	92.80
(ii) the detection of acute Hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient (Item is subject to rules 19 and 25)
69445		Detection of Hepatitis C viral RNA in a patient undertaking antiviral therapy for chronic HCV hepatitis (including a service described in item 69444) — 1 test (Item is subject to rule 25)	92.80
69471		Test of cell-mediated immunity in blood for the detection of active tuberculosis or atypical mycobacterial infection in an immunosuppressed or immunocompromised patient — 1 test

69472		Detection of antibodies to Epstein Barr Virus using specific serology — 1 test	15.75
69474		Detection of antibodies to Epstein Barr Virus using specific serology — 2 or more tests	28.85
69475		Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D — 1 test, including: (a) Hepatitis A antibody test; or (b) Hepatitis B antibody or antigen test; or (c) Hepatitis C antibody test; or (d) Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive (Item is subject to rule 11)	15.75
69478		Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D — 2 tests, including: (a) Hepatitis A antibody test; or (b) Hepatitis B surface or core antibody test; or (c) Hepatitis B surface antigen test; or (d) Hepatitis B ‘e’ antibody or ‘e’ antigen test; or (e) Hepatitis C antibody test; or (f) Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive (Item is subject to rule 11)	29.45
69481		Investigation of infectious causes of acute or chronic hepatitis — 3 tests, including: (a) Hepatitis A antibody test; or (b) Hepatitis B core antibody test; or (c) Hepatitis B ‘e’ antibody or ‘e’ antigen test; or (d) Hepatitis B surface antibody or surface antigen test; or (e) Hepatitis C antibody test; or (f) Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive (Item is subject to rule 11)	40.80
69484		Supplementary test for Hepatitis B surface antigen or Hepatitis C antibody using a different assay on a specimen that yielded a reactive result on initial testing	17.20
Group P4 — Immunology
71057		Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate: (a) protein classes; or (b) presence and amount of paraprotein; including the preliminary quantitation of total protein, albumin and globulin — 1 specimen type	36.30
71058		Examination as described in item 71057 of 2 or more specimen types	51.40
71059		Electrophoresis and immunofixation, immunoelectrophoresis or isoelectric focussing of: (a) urine for detection of Bence Jones proteins; or (b) serum, plasma or other body fluid; and characterisation, if detected, of a paraprotein or cryoglobulin not previously characterised — examination of 1 specimen type (eg serum, urine or CSF)	29.70
71060		Examination as described in item 71059 of 2 or more specimen types	44.80
71062		Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient’s serum for comparison purposes — 1 or more tests	44.80
71064		Detection and quantitation of cryoglobulins or cryofibrinogen — 1 or more tests	21.10
71066		Quantitation of total immunoglobulin A (by any method) in serum, urine, or other body fluid — 1 test	14.80
71068		Quantitation of total immunoglobulin G (by any method) in serum, urine, or other body fluid — 1 test	14.80
71069		2 tests described in item 71066, 71068, 71072 or 71074	23.15
71071		3 or more tests described in item 71066, 71068, 71072 or 71074	31.50
71072		Quantitation of total immunoglobulin M (by any method) in serum, urine, or other body fluid — 1 test	14.80
71073		Quantitation of all 4 immunoglobulin G subclasses	108.00
71074		Quantitation of total immunoglobulin D (by any method) in serum, urine, or other body fluid — 1 test	14.80
71075		Quantitation of immunoglobulin E (total) — 1 test (Item is subject to rule 25)	23.40
71077		Quantitation of immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis — 1 test (Item is subject to rule 25)	27.55
71079		Detection of specific immunoglobulin G or E antibodies to single or multiple potential allergens (Item is subject to rule 25)	27.30
71081		Quantitation of total haemolytic complement	41.25
71083		Quantitation of complement components C3 and C4 or properdin factor B — 1 test	20.50
71085		2 tests described in item 71083	29.45
71087		3 or more tests described in item 71083	38.35
71089		Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this table — 1 test	29.65
71091		2 tests described in item 71089	53.70
71093		3 or more tests described in item 71089	77.80
71095		Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years	41.25
71097		Antinuclear antibodies — detection in serum or other body fluids, including quantitation if required	24.85
71099		Double-stranded DNA antibodies — quantitation by 1 or more methods other than the Crithidia method	27.00
71101		Antibodies to 1 or more extractable nuclear antigens — detection in serum or other body fluids	17.70
71103		Characterisation of an antibody detected in a service described in item 71101 (including that service)	52.95
71106		Rheumatoid factor — detection by any technique in serum or other body fluids, including quantitation if required	11.50
71109		Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) — detection, including quantitation if required, of 1 antibody	35.15
71113		Detection of 2 antibodies described in item 71109	48.25
71115		Detection of 3 antibodies described in item 71109	61.35
71117		Detection of 4 or more antibodies described in item 71109	74.45
71119		Antibodies to tissue antigens not elsewhere specified in this table — detection, including quantitation if required, of 1 antibody	17.65
71121		Detection of 2 antibodies specified in item 71119	21.15
71123		Detection of 3 antibodies specified in item 71119	24.65
71125		Detection of 4 or more antibodies specified in item 71119	28.15
71127		Functional tests for lymphocytes — quantitation, other than by microscopy, of: (a) proliferation induced by 1 or more mitogens; or (b) proliferation induced by 1 or more antigens; or	179.45
(c) estimation of 1 or more mixed lymphocyte reactions; including a test described in item 65066 or 65070 (if performed) (Item is subject to rule 25)
71129		2 tests described in item 71127	221.65
71131		3 or more tests described in item 71127	263.90
71133		Investigation of recurrent infection, by qualitative assessment, for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (NBT) reduction test	10.55
71134		Investigation of recurrent infection, by quantitative assessment, of oxidative pathways by flow cytometric techniques, including a test described in item 71133 (if performed)	105.85
71135		Quantitation of neutrophil function, comprising at least 2 of the following: (a) chemotaxis; (b) phagocytosis; (c) oxidative metabolism; (d) bactericidal activity; including any test described in item 65066, 65070, 71133 or 71134 (if performed) (Item is subject to rule 25)	211.60
71137		Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens (Item is subject to rule 25)	30.80
71139		Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid	105.85
71141		Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens	200.85
71143		Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue	264.55
71145		Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed) on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid	431.95
71146		Enumeration of CD34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count	105.85
71147		HLA-B27 typing	41.25
71149		Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147	110.15
71151		Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) — phenotyping or genotyping of 2 or more antigens	120.95
71153		Testing, for assessment or diagnosis of systemic inflammatory disease or vasculitis, for the presence of an antibody by 1 of the following tests: (a) antineutrophil cytoplasmic antibody (ANCA) immunofluorescence test; (b) antineutrophil proteinase 3 antibody (PR3 ANCA) test; (c) antimyeloperoxidase antibody (MPO ANCA) test; (d) antiglomerular basement membrane antibody (GBM ANCA) test (Item is subject to rule 23)	35.15
71155		Testing for the presence of 2 antibodies by tests mentioned in item 71153 (Item is subject to rule 23)	48.25
71157		Testing for the presence of 3 antibodies by tests mentioned in item 71153 (Item is subject to rule 23)	61.35
71159		Testing for the presence of 4 antibodies by tests mentioned in item 71153 (Item is subject to rule 23)	74.45
71163		Detection of 1 of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes, including a service described in item 71066 (if performed): (a) antibodies to gliadin; (b) antibodies to endomysium; (c) antibodies to tissue transglutaminase 1 test	25.15
71164		2 or more tests mentioned in item 71163, including a service described in item 71066 (if performed)	40.60
Group P5 — Tissue pathology
72813		Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens (Item is subject to rule 13)	72.15
72816		Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 separately identified specimen (Item is subject to rule 13)	87.10
72817		Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 2 to 4 separately identified specimens (Item is subject to rule 13)	97.45
72818		Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 5 or more separately identified specimens (Item is subject to rule 13)	107.75
72823		Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 separately identified specimen (Item is subject to rule 13)	97.95
72824		Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 2 to 4 separately identified specimens (Item is subject to rule 13)	142.30
72825		Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 5 to 7 separately identified specimens (Item is subject to rule 13)	181.45
72826		Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 8 or more separately identified specimens (Item is subject to rule 13)	195.90
72830		Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens (Item is subject to rule 13)	190.75
72836		Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens (Item is subject to rule 13)	293.85
72844		Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system — 1 or more tests	30.95
72846		Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 antibodies except those mentioned in item 72848 (Item is subject to rule 13)	43.30
72847		Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 4 or more antibodies (Item is subject to rule 13)	57.75
72848		Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 of the following antibodies: (a) oestrogen; (b) progesterone; (c) c-erb-B2 (HER2) (Item is subject to rule 13)	51.55
72851		Electron microscopic examination of biopsy material — 1 separately identified specimen (Item is subject to rule 13)	185.60
72852		Electron microscopic examination of biopsy material — 2 or more separately identified specimens (Item is subject to rule 13)	247.45
72855		Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear — 1 separately identified specimen (Item is subject to rule 13)	185.60
72856		Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear — 2 to 4 separately identified specimens (Item is subject to rule 13)	247.45
72857		Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear — 5 or more separately identified specimens (Item is subject to rule 13)	288.70
Group P6 — Cytology
73043		Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes — 1 or more tests	23.00
73045		Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053), including any Group P5 service (if performed), 1 or more tests on: (a) specimens resulting from washings or brushings from sites not specified in item 73043; or (b) a single specimen of sputum or urine; or (c) 1 or more specimens of other body fluids	48.95
73047		Cytology of a series of 3 sputum or urine specimens for malignant cells	95.35
73049	Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues		69.60
73051		Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues, if: (a) the aspiration is performed by a recognised pathologist; or (b) a recognised pathologist attends the aspiration and performs a cytological examination during the attendance	171.50
73053		Cytology of a smear from cervix, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist — each examination: (a) for the detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or (b) if a further specimen is taken due to an unsatisfactory smear taken for the purposes of paragraph (a); or (c) if there is inadequate information provided to use item 73055	19.60
73055		Cytology of a smear from cervix, not associated with item 73053, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist — each test: (a) for the management of previously detected abnormalities including precancerous or cancerous conditions; or (b) for the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia	19.60
73057		Cytology of a smear from vagina, not associated with item 73053 or 73055, and not to monitor hormone replacement therapy, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist — each test	19.60
73059		Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 antibodies except those mentioned in item 73061 (Item is subject to rule 13)	43.30
73060		Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 4 or more antibodies (Item is subject to rule 13)	57.75
73061		Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 of the following antibodies:

(a) oestrogen;

(b) progesterone;

(Item is subject to rule 13)		51.55
Group P7 — Genetics
73287		Chromosome studies, including preparation, count, karyotyping and identification by banding techniques of 1 or more of any tissue or fluid except blood — 1 or more tests	401.45
73289		Chromosome studies, including preparation, count, karyotyping and identification by banding techniques of blood — 1 or more tests	365.20
73300		Detection of genetic mutation of the FMR1 gene by nucleic acid amplification (NAA) where: (a) the patient exhibits 1 or more of the clinical features of fragile X (A) syndrome, including intellectual disabilities; or (b) the patient has a relative with a fragile X (A) mutation 1 or more tests	103.10
73305		Detection of genetic mutation of the FMR1 gene by Southern Blot, if the results of a service performed in item 73300 are inconclusive	206.20
Group P8 — Infertility and pregnancy tests
73521		Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test)	9.80
73523		Semen examination (other than post-vasectomy semen examination), including: (a) measurement of volume, sperm count and motility; and (b) examination of stained preparations; and (c) morphology; and (d) (if performed) differential count and 1 or more chemical tests (Item is subject to rule 25)	42.50
73525		Sperm antibodies — sperm-penetrating ability — 1 or more tests	28.85
73527		Human chorionic gonadotrophin (HCG) — detection in serum or urine by 1 or more methods for diagnosis of pregnancy — 1 or more tests	10.20
73529		Human chorionic gonadotrophin (HCG), quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of threatened abortion, or follow up of abortion or diagnosis of ectopic pregnancy, including any services performed in item 73527 — 1 test	29.15
Group P9 — Simple basic pathology tests
73801	Semen examination for presence of spermatozoa		6.95
73802	Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count — 1 test		4.60
73803	2 tests described in item 73802		6.40
73804	3 or more tests described in item 73802		8.20
73805	Microscopy of urine, whether stained or not, or catalase test		4.60
73806	Pregnancy test by 1 or more immunochemical methods		10.20
73807	Microscopy for wet film other than urine, including any relevant stain		6.95
73808	Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807		8.70
73809	Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method		2.35
73810	Microscopy for fungi in skin, hair or nails — 1 or more sites		6.95
73811	Mantoux test		11.30
Group P10 — Patient episode initiation
73901		Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory	8.25
73903		Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 from a person who is an in-patient of a hospital other than a recognised hospital	14.75
73905		Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital	8.25
73907		Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected: (a) until 30 November 2001 — in a licensed collection centre (within the meaning of Part IIA of the Act); or (b) after that date — in an approved collection centre	17.40
73909		Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital	17.70
73910		Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing	10.30
73912		Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in a residential care facility or institution	17.70
73913		Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905, 73907 or items in Group P9) if the specimen is collected from the person by the person	9.80
73915		Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner	9.80
Group P11 — Specimen referred
73921	Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another approved pathology authority (Item is subject to rules 14, 15 and 16)		10.30
Group P12 — Management of bulk-billed services
74990		A pathology service to which an item in this table (other than this item or item 74991) applies if: (a) the service is an unreferred service; and (b) the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and (c) the person is not an admitted patient of a hospital or day-hospital facility; and (d) the service is bulk-billed in respect of the fees for: (i) this item; and (ii) the other item in this table applying to the service	5.85
74991		A pathology service to which an item in this table (other than this item or item 74990) applies if: (a) the service is an unreferred service; and (b) the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and (c) the person is not an admitted patient of a hospital or day-hospital facility; and	8.80
(d) the service is bulk-billed in respect of the fees for: (i) this item; and (ii) the other item in this table applying to the service; and
(e) the service is provided at, or from, a practice location in: (i) a regional, rural or remote area; or (ii) Tasmania; or (iii) a geographical area included in any of the following SSD spatial units: (A) Beaudesert Shire Part A (B) Belconnen
(C) Darwin City (D) Eastern Outer Melbourne (E) East Metropolitan (F) Frankston City
(G) Gosford-Wyong (H) Greater Geelong City Part A (I) Gungahlin-Hall (J) Ipswich City (Part in BSD) (K) Litchfield Shire (L) Melton-Wyndham (M) Mornington Peninsula Shire (N) Newcastle (O) North Canberra (P) Palmerston-East Arm (Q) Pine Rivers Shire (R) Queanbeyan
(S) South Canberra (T) South Eastern Outer Melbourne (U) Southern Adelaide (V) South West Metropolitan (W) Thuringowa City Part A (X) Townsville City Part A (Y) Tuggeranong (Z) Weston Creek-Stromlo (ZA) Woden Valley (ZB) Yarra Ranges Shire Part A; or (iv) the geographical area included in the SLA spatial unit of Palm Island (AC)

Part 4 Abbreviations

Note A drug that is not mentioned in this Part must be written in full.

Test	Abbreviation	Item
Abnormal haemoglobins	AH	65117
Acetoacetate	ACAT	66500
Acetylcholine receptor — tissue antigens — antibodies	ARA	71109
Acid phosphatase	ACP	66500
Actinomycetes — microbial antibody testing	ACT	69384
Activated Protein C resistance	APC	65132–36, 65142, 65171
Adenovirus — microbial antibody testing	ADE	69384
Adrenal cortex — tissue antigens — antibodies	ADR	71109
Adrenocorticotrophic hormone (ACTH)	ACTH	66695
AFB microscopy and culture of sputum — 1 specimen	AFB1	69324
AFB microscopy and culture of sputum — 2 specimens	AFB2	69327
AFB microscopy and culture of sputum — 3 specimens	AFB3	69330
Alanine aminotransferase	ALT	66500
Albumin	ALB	66500
Alcohol (ethanol)	ETOH	66626, 66800
Aldosterone	ALDS	66695
Alkaline phosphatase	ALP	66500
Alkaline phosphatase — isoenzymes	ALPI	66641
Alpha-1-antitrypsin	AAT	66635
Alpha-fetoprotein	AFP	66650–53, 66743, 66750, 66751
Aluminium	AL	66672–73
Aluminium — renal dialysis	ALR	66671
Amikacin	66800
Amino acids	AA	66752
Amiodarone	AMIO	66812
Amitriptyline	AMIT	66812
Ammonia	NH3	66500
Amniotic fluid examination	AFE	66749
Amylase	AMS	66500
Amylobarbitone	AMYL	66812
Androstenedione	ANDR	66695
Angiotensin converting enzyme	ACE	66758
Antibiotic and antimicrobial chemotherapeutic agents — quantitation	QAA	66800, 66812
Antibodies to extractable nuclear antigens — characterisation of antibodies if positive ENA	ENAP	71103
Antibodies to extractable nuclear antigens — detection	ENA	71101
Antibodies to nuclear antigens — detection	ANA	71097
Antibodies to nuclear antigens — quantitation and measurement of DNA binding if positive ANA	ANAP	71099
Antibodies to tissue antigens — acetylcholine receptor	ARA	71109
Antibodies to tissue antigens — adrenal cortex	ADR	71109
Antibodies to tissue antigens — ANCA- myeloperoxidase	MPO	71153
Antibodies to tissue antigens — ANCA-PR3	PR3	71153
Antibodies to tissue antigens — anti-actin	AACT	71119
Antibodies to tissue antigens — anti-endomysial	EMA	71163
Antibodies to tissue antigens — cardiolipin	ACL	71109
Antibodies to tissue antigens — coeliac disease panel	CLC	71163–64
Antibodies to tissue antigens — gastric parietal cell	PCA	71119
Antibodies to tissue antigens — gliadin IgA	GLIA	71163
Antibodies to tissue antigens — gliadin IgG	GLIG	71163
Antibodies to tissue antigens — glomerular basement membrane	GBM	71153
Antibodies to tissue antigens — heart	AHE	71109
Antibodies to tissue antigens — histone	AHI	71109
Antibodies to tissue antigens — insulin receptor antibodies	INSA	71109
Antibodies to tissue antigens — intercellular cement substance of skin	ICCS	71109
Antibodies to tissue antigens — intrinsic factor	AIF	71109
Antibodies to tissue antigens — islet cell	AIC	71109
Antibodies to tissue antigens — Jo-1	JO1	71119
Antibodies to tissue antigens — keratin	KERA	71119
Antibodies to tissue antigens — liver/kidney microsomes	LKA	71119
Antibodies to tissue antigens — lymphocyte	ALY	71109
Antibodies to tissue antigens — mitochondria	MA	71119
Antibodies to tissue antigens — neuron	ANE	71109
Antibodies to tissue antigens — neutrophil cytoplasm	ANCA	71153
Antibodies to tissue antigens — ovary	AOV	71109
Antibodies to tissue antigens — parathyroid	PTHA	71109
Antibodies to tissue antigens — platelet	APA	71109
Antibodies to tissue antigens — PM-Sc1	PM1	71119
Antibodies to tissue antigens — reticulin	RCA	71119
Antibodies to tissue antigens — salivary gland	ASG	71109
Antibodies to tissue antigens — Scl-70	SCL	71119
Antibodies to tissue antigens — skeletal muscle	SLA	71109
Antibodies to tissue antigens — skin basement membrane	SKA	71109
Antibodies to tissue antigens — smooth muscle	SMA	71119
Antibodies to tissue antigens — thyroglobulin	ATG	71109
Antibodies to tissue antigens — thyroid microsome	TMA	71109
Antibodies to tissue antigens — tissue transglutaminase	TTG	71163
Antibodies to tissue antigens — TSH receptor antibody test	TSHA	71109
Antibody testing, microbial (see Microbial)
Antigen testing, microbial (see Microbial)
Antithrombin III	ATH	65132–36, 65142, 65171
Anti-Xa activity	QAXA	65147
Anus — cytology on specimens from	SMCY	73043
Apolipoprotein B/A1 ratio	APO	66536
Arginine infusion	ARIN	66689
Arsenic	AS	66672–73
Aspartate aminotransferase	AST	66500
Aspergillus — microbial antibody testing	ASP	69384
Avian precipitins (bird fancier’s disease) — microbial antibody testing	APP	69384
B12 vitamin	B12	66599
Barbiturate	BARB	66800, 66812
Beryllium	BE	66672–73
Beta-2-microglobulin	BMIC	66629
Beta-hydroxybutyrate	BHYB	66500
Bicarbonate	HCO3	66500
Bilirubin (all fractions)	BILI	66500
Bilirubin (all fractions) — in urine	UBIL	66500
Bilirubin (all fractions) — neonatal	BILN	66749
Bird fancier’s disease (see avian precipitins)	APP	69384
Blastomyces — microbial antibody testing	BLM	69384
Blood — compatibility testing	XMAT	65099–108
Blood — culture	BC	69354–60
Blood — faecal occult	FOB	66764–70
Blood — film	BF	65066
Blood — full examination	FBE	65070
Blood — gases	GAS	66566
Blood — group and blood group antibodies	BGAB	65096
Blood — group antibodies	BGA	65111
Blood — group systems	BGS	65093
Blood — grouping — ABO and RH (D antigen)	BG	65090
Blood — viscosity	VISC	65060
Body cavities — aspirations of — microscopy and culture of material from	MCPO	69321
Body fluids — cytology	BFCY	73045
Bone — low mineral densities	CBLB	66773
Bone — metabolic bone disease	CBMB	66776
Bone marrow examination — aspirate	BMEA	65087
Bone marrow examination — trephine	BMET	65084
Bordetella pertussis — microbial antibody testing	BOR	69384
Borrelia burgdorferi — microbial antibody testing	BOB	69384
Breath hydrogen test	BHT	66674
Bromide	BRMD	66812
Brucella — microbial antibody testing	BRU	69384
C-l esterase inhibitor — functional	CEIF	66647
C-l esterase inhibitor — quantitation	CEIQ	66644
CA-15.3 antigen	CA15	66650
CA-19.9 antigen	CA19	66650
CA-125 antigen	C125	66650
Cadmium	CD	66672–73
Caeruloplasmin	CPLS	66632
Calcitonin	CALT	66695
Calcium — ionised	ICA	66584
Calcium (total or corrected for albumin)	CA	66500
Calculus analysis	CALC	66590
Campylobacter jejuni — microbial antibody testing	CAM	69384
Candida — microbial antibody testing	CAN	69384
Carbamazepine (Tegretol)	CARB	66800
Carboxyhaemoglobin	COHB	65117
Carcinoembryonic antigen	CEA	66650
Cardiac enzymes	CE	66506
Cardiolipin — tissue antigens — antibodies	ACL	71109
Catecholamines	CAT	66779
Cell mediated immunity — delayed type — hypersensitivity test	CMI	71137
Cell-mediated immunity in blood	CMIB	69471
Cervix — cytology — abnormalities	CCRA	73055
Cervix — cytology — routine	CCR	73053
Cervix — microscopy and culture of material from	MCGR	69312
Cervix — microscopy, culture and Chlamydia of material from	MCCH	69315
Characterisation of antibodies if positive ENA	ENAP	71103
Chemicals, toxic (ingested or absorbed) — assays	DRGO	66623
Chlamydia — investigation by any method	CHLM	69369
Chlamydia — investigation by any method and N gonorrhoea by NAA methods	CHGO	69370
Chlamydia — microbial antibody testing	CHL	69384
Chlamydia — microbial antigen testing	MCCH	69315, 69369
Chloral hydrate	CHHY	66812
Chlorazepate	CHZP	66812
Chloride	CL	66500
Chloroquine	CLOQ	66812
Chlorpromazine	CHLO	66812
Cholesterol	CHOL	66500
Cholesterol — HDL	HDLC	66536
Cholinesterase	CHSE	66758
Chorionic gonadotrophin — quantitation	HCG	66650–53, 66750, 66751, 73529
Chorionic gonadotrophin — detection for pregnancy diagnosis	HCGP	73527–29
Chromium	CR	66672–73
Chromosome identification — studies — blood	CSB	73289
Chromosome identification — studies — other than blood	CS	73287
Chromosome identification and banding	73287–89
Cimetidine	CMTD	66812
Clobazam	CLOB	66812
Clomipramine	CLOM	66812
Clonazepam (Rivotril)	CLON	66812
Clostridium difficile — microbial antigen testing	CLDT	69363
Coagulation factor inhibitors by Bethesda assay	BETH	65159
Coagulation — factors (see individual factors)
Coagulation — studies	COAG	65120
Coccidioides — microbial antibody testing	CCC	69384
Coeliac antibodies	CLC	71163–64
Cold agglutinins	CAG	65114
Collagen — low bone	CBLB	66773
Collagen — metabolic disease	CBMB	66776
Compatibility testing	XMAT	65099–108
Complement, total haemolytic	COM	71081
Complement, total haemolytic — components C3	C3	71083
Complement, total haemolytic — components C4	C4	71083
Complement, total haemolytic — other components	COMP	71089
Complement, total haemolytic — properdin factor B	PFB	71083
Copper	CU	66669–70
Cortisol	CORT	66695
Coxsackie B1-6 — microbial antibody testing	COX	69384
C-Peptide	CPEP	66695
C-reactive protein	CRP	66500
Creatine kinase	CK	66500
Creatine kinase — isoenzymes	CKI	66518
Creatine kinase — isoenzymes (electrophoresis)	CKIE	66518
Creatinine	C	66500
Cryofibrinogen — detection and quantitation	CFID	71064
Cryoglobulins — characterisation by electrophoresis and immunoelectrophoresis or immunofixation or isoelectric focussing	RYO	71059
Cryoglobulins — detection and quantitation	CGLD	71064
Cryptococcal antigen — microbial antigen testing	CRYN	69372
Cryptococcus — microbial antibody testing	CRY	69384
CSF — microscopy and culture of material from	MCPO	69321
CSF antigens — group B streptococcus	STB	69372
CSF antigens — Haemophilus influenzae	HI	69372
CSF antigens — Neisseria meningitidis	NMG	69372
CSF antigens — Streptococcus pneumoniae	SPN	69372
Cultural examination of faeces	FCS	69345
Cyclic AMP	CAMP	66695
Cyclosporin A	CLSA	66812
Cystine — qualitative	UCYS	66752
Cystine — quantitative	CYST	66752
Cytology — fine needle aspiration of solid tissues	FNCY	73049
Cytology — fine needle aspiration of solid tissues — aspiration or attendance by a pathologist	FNCP	73051
Cytology — from 3 sputum or urine specimens	SPCY	73047
Cytology — from body fluids, sputum (1 specimen), urine, washings or brushings	BFCY	73045
Cytology — from cervix — abnormalities	CCRA	73055
Cytology — from cervix — routine	CCR	73053
Cytology — from skin, nipple discharge, lip, mouth, nose or anus	SMCY	73043
Cytology — from vagina	CVO	73057
Cytomegalovirus — microbial antibody testing	CMV	69384
Cytomegalovirus serology in pregnancy — microbial antibody testing	CMVP	69405–11
D vitamin	VITD	66608
D-dimer test	DD	65120
Dehydroepiandrosterone sulphate (DHEAS)	DHEA	66695
Dengue — microbial antibody testing	DEN	69384
11-Deoxycortisol	DCOR	66695
Desipramine	DESI	66812
Dexamethasone	DXST	66686
Dexamethasone — suppression test	DEXA	66686
DHEAS (Dehydroepiandrosterone sulphate)	DHEA	66695
Diazepam	DIAZ	66812
Differential cell count	DIFF	65070
Digoxin	DIG	66800
Dihydrotestosterone	DHTS	66695
Diphenylhydantoin (Dilantin)	DIL	66812
Diphtheria — microbial antibody testing	DIP	69384
Direct Coombs test	CMBS	65114
Disopyramide (Rythmodan)	DISO	66800
DNA binding — quantitation and measurement if positive ANA	ANAP	71099
DNA (double-stranded DNA) antibody	DSDNA	71099
Donath Landsteiner antibody test	DLAT	65075
Down’s syndrome and neural tube defects	NTDD	66750, 66751
Doxepin hydrochloride	DOXE	66812
Drugs — abuse treatment programme — assay	DATP	66626
Drugs — inappropriate dosage — assay	DRGO	66623
Drugs — therapeutic — assay (see individual drugs)	66800, 66812
Dynamic function tests	GHSE	66686
Ear — microscopy and culture of material from	MCSW	69303
Echinococcus — microbial antibody testing	ECC	69384
Echis test	ECHI	65120
ECHO-coxsackie group — microbial antibody testing	ECH	69384
Electrolytes	E	66509
Electron microscopy of biopsy material	EM	72851–52
Electrophoresis, and immunofixation or immunoelectrophoresis or isoelectric focussing — characterisation of cryoglobulins	RYO	71059
Electrophoresis, and immunofixation or immunoelectrophoresis or isoelectric focussing — characterisation of paraprotein	PRYO	71059
Electrophoresis, to demonstrate — creatine kinase isoenzymes	CKIE	66518
Electrophoresis, to demonstrate — lactate dehydrogenase isoenzymes	LDI	66641
Electrophoresis, to demonstrate — lipoprotein subclasses	LEPG

Electrophoresis, to demonstrate — quantitation of protein classes, or paraprotein	EPPI	71057–58
Elements (see individual elements)
Endomysium antibodies	EMA	71163
Entamoeba histolytica — microbial antibody testing	AMO	69384
Enzyme assays of solid tissue or tissues	ENZS	66683
Enzyme histochemistry of skeletal muscle	EHSK	72844
Eosinophil cationic protein	ECP	71095
Epstein Barr virus — microbial antibody testing	EBV	69472–74
Erythrocyte — assessment of haemolysis	ERYH	65075
Erythrocyte — assessment of metabolic enzymes	ERYM	65075
Erythrocyte — count	RCC	65070
Erythrocyte — sedimentation rate	ESR	65060
Ethanol (alcohol)	ETOH	66626, 66800
Ethosuximide (Zarontin)	ETHO	66800
Extractable nuclear antigens — detection of antibodies to	ENA	71101
Eye — microscopy and culture of material from	MCSW	69303
Factor II	FII	65150
Factor V	FV	65150
Factor V Leiden mutation	FVLM	65168, 65174
Factor VII	FVII	65150
Factor VIII	VIII	65150
Factor IX	FIX	65150
Factor X	FX	65150
Factor XI	FXI	65150
Factor XII	FXII	65150
Factor XIII	XIII	65150
Factor XIII deficiency test	F13D	65120
Faecal antigen test for Helicobacter pylori	FAHP	69372
Faecal blood	FOB	66764–70
Faecal fat	FFAT	66674
Faecal fat — haemoglobin	FFH	66764
Faecal fat — reducing substances	FRS	66761
Faeces — culture	FCS	69345
Faeces — microscopy for parasites	OCP	69336–39
Ferritin (see also Iron studies)	FERR	66593
Fibrin monomer	FM	65120
Fibrinogen	FIB	65120
Fibrinogen — degradation products	FDP	65120
Fitzgerald factor	FGF	65150
Flecainide	FLEC	66812
Fletcher factor	FF	65150
Fluorescent treponemal antibody — absorption test (FTA-ABS) — microbial antibody testing	FTA	69384
Fluoxetine	FLUX	66812
Foetal red blood cells — Kliehauer	KLEI	65162
Folate — red cell	RCF	66599
Follicle stimulating hormone (FSH)	FSH	66695
Fragile X	FXS	73300, 73305
Frozen section diagnosis of biopsy material	FS	72855–56
Fructosamine	FRUC	66557
Full blood examination	FBE	65070
Gamma glutamyl transpeptidase	GGT	66500
Gastric parietal cell — tissue antigens — antibodies	PCA	71119
Gastrin	GAST	66695
Gentamicin	66800
Gliadin IgA — tissue antigens — antibodies	GLIA	71163
Globulin	GLOB	66500
Glomerular basement membrane — tissue antigens — antibodies	GBA	71109
Glucagon	GLGO	66695
Glucagon stimulation test	GSTC	66689
Glucose	GLUC	66500
Glucose — tolerance test	GTT	66542
Glycosylated haemoglobin (Hb Alc)	GHB	66551
Gold	AU	66672–73
Gonadotrophin	GRHS	66689
Group B streptococcus — CSF antigens	STB	69372
Group B streptococcus — microbial antigen testing	STB	69372
Group P9 — simple basic pathology tests	73801–11
Growth hormone	GH	66695
Growth hormone — stimulation by exercise or L-dopa	GHSE	66686
Growth hormone — suppression by dexamethasone or glucose	GHSG	66686
Haematocrit	HCT	65070
Haemochromatosis	FEUP	66794
Haemoglobin	HB	65060
Haemoglobinopathy tests	HMGP	65081
Haemophilus influenzae — CSF antigens	HI	69372
Haemophilus influenzae — microbial antibody testing	HUS	69384
Haemophilus influenzae — microbial antigen testing	HI	69372
Haloperidol	HALO	66812
Haptoglobins	HGLB	66632
HDL cholesterol	HDLC	66536
Heart — tissue antigens — antibodies	AHE	71109
Heparin — test	HEPR	65144
Hepatitis B or C confirmatory test	HSVP	69484
Hepatitis C — detection	RNAC	69444
Hepatitis C — genotype	GHCV	69443
Hepatitis C — quantitation	THCV	69442
Hepatitis investigation — 3 markers	HEP3	69481
Hepatitis serology — in pregnancy	HEPP	69405–13
Hepatitis status or carriage — 1 marker	HEP1	69475
Hepatitis status or carriage — 2 markers	HEP2	69478
Hepatitis status or carriage — 3 markers	HEP3	69481
Herpes simplex virus — direct detection from clinical material	HSV	69375
Herpes simplex virus — investigation by culture	HSVC	69375
Herpes simplex virus — microbial antibody testing	HPA	69384
Herpes simplex virus — microbial antigen testing	HSV	69375
Heterophil antibodies	IM	65114
HIAA (hydroxyindoleacetic acid)	HIAA	66779
Histamine	HIAM	66779
Histone — tissue antigens — antibodies	AHI	71109
Histopathology of biopsy material	HIST	72813–36
Histoplasma — microbial antibody testing	HIP	69384
HIV — antiretroviral therapy	TVLT	69381
HIV — cerebrospinal fluid	CVLT	69382
HIV — monitoring	MVLT	69378
HLA typing — HLA class 1	HLA1	71149
HLA typing — HLA class 2	HLA2	71151
HLA typing — HLA-B27	HLAB	71147
HMMA (hydroxy-3-methoxymandelic acid, previously known as VMA)	HMMA	66779
HMPG (hydroxy-methoxy phenylethylene glycol)	HMPG	66779
Homovanillic acid	HVA	66779
Hormone receptor assay — breast	HRA	66662
Hormone receptor assay — ovary	HRO	66662
Hormones — stimulation by exercise or L-dopa	GHSE	66686
Hormones — 11 deoxycortisol	DCOR	66695
Hormones — adrenocorticotrophic hormone	ACTH	66695
Hormones — aldosterone	ALDS	66695
Hormones — androstenedione	ANDR	66695
Hormones — calcitonin	CALT	66695
Hormones — cortisol	CORT	66695
Hormones — C-Peptide	CPEP	66695
Hormones — cyclic AMP	CAMP	66695
Hormones — dehydroepiandrosterone sulphate (DHEAS)	DHEA	66695
Hormones — dihydrotestosterone	DHTS	66695
Hormones — follicle stimulating hormone	FSH	66695
Hormones — gastrin	GAST	66695
Hormones — glucagon	GLGO	66695
Hormones — gonadotrophin	GRHS	66689
Hormones — growth hormone	GH	66695
Hormones — growth hormone — stimulation by exercise or L-dopa	GHSE	66686
Hormones — growth hormone — suppression by dexamethasone or glucose	GHSG	66686
Hormones — hormone receptor assay — breast	HRA	66662
Hormones — hormone receptor assay — ovary	HRO	66662
Hormones — human chorionic gonadotrophin — detection for pregnancy diagnosis	HCGP	73527, 73529
Hormones — human chorionic gonadotrophin — quantitation	HCG	66650–53, 66750, 66751, 73529
Hormones — hydroxyprogesterone	OHP	66695
Hormones — insulin	INS	66695
Hormones — insulin, hypoglycaemia test	INHY	66689
Hormones — luteinizing hormone	LH	66695
Hormones — oestradiol	E2	66695
Hormones — oestriol	E3	66750, 66751
Hormones — oestrone	E1	66695
Hormones — parathyroid hormone	PTH	66695
Hormones — pentagastrin	PSTR	66689
Hormones — progesterone	PROG	66695
Hormones — prolactin	PROL	66695
Hormones — renin	REN	66695
Hormones — sex hormone binding globulin	SHBG	66695
Hormones — somatomedin	SOMA	66695
Hormones — suppression by dexamethasone or glucose	GHSG	66686
Hormones — testosterone	TES	66695
Hormones — urine steroid fraction or fractions	USF	66695
Hormones — vasoactive intestinal peptide	VIP	66695
Hormones — vasopressin	ADH	66695
Hormones and hormone binding proteins (see individual hormones and proteins)	66695
Huhner’s test	HT	73521
Human chorionic gonadotrophin — detection for pregnancy diagnosis	HCGP	73527, 73529
Human chorionic gonadotrophin — quantitation	HCG	66650–53, 66750, 66751, 73529
HVA (homovanillic acid)	HVA	66779
Hydatid — microbial antibody testing	HYD	69384
Hydroxy methoxy phenylethylene glycol	HMPG	66779
Hydroxy-3-methoxymandelic acid (previously known as VMA)	HMMA	66779
Hydroxychloroquine	HOCQ	66812
Hydroxyindoleacetic acid	HIAA	66779
Hydroxyprogesterone	OHP	66695
Hydroxyproline	HYDP	66752
Imipramine	IMIP	66812
Immediate frozen section diagnosis of biopsy material	FS	72855–56
Immunocyto. 1-3 antibodies	ICC	73059, 73061
Immunocyto. 4+ antibodies	ICC1	73060
Immunoelectrophoresis and electrophoresis —characterisation of cryoglobulins	RYO	71059
Immunoelectrophoresis and electrophoresis —characterisation of paraprotein	PPRO	71059
Immunoglobulins — A	IGA	71066
Immunoglobulins — D	IGD	71074
Immunoglobulins — E (total)	IGE	71075–79
Immunoglobulins — G	IGG	71068
Immunoglobulins — G, 4 subclasses	SIGG	71073
Immunoglobulins — M	IGM	71072
Immunohistochemical investigation of biopsy material	HIS	72846–48
Infectious mononucleosis	IM	69384
Influenza A — microbial antibody testing	FLA	69384
Influenza B — microbial antibody testing	FLB	69384
Insulin	INS	66695
Insulin — hypoglycaemia test	INHY	66689
Insulin — tissue antigens — antibodies	AINS	71109
Insulin receptor antibodies — tissue antigens — antibodies	INSA	71109
Intercellular cement substance of skin — tissue antigens — antibodies	ICCS	71109
Intestinal disaccharidases	INTD	66680
Intrinsic factor — tissue antigens — antibodies	AIF	71109
Iron studies (iron, transferrin and ferritin)	IS	66596
Islet cell — tissue antigens — antibodies	AIC	71109
Isoelectric focussing and electrophoresis —characterisation of cryoglobulins	RYO	71059
Isoelectric focussing and electrophoresis —characterisation of paraprotein	PPRO	71059
Jo-1 — tissue antigens — antibodies	JO1	71119
Keratin — tissue antigens — antibodies	KERA	71119
Kleihauer test	KLEI	65162
Lactate	LACT	66500
Lactate — dehydrogenase	LDH	66500
Lactate — dehydrogenase isoenzymes	LDI	66641
Lamellar body phospholipid	LBPH	66749
Lead	PB	66665
Lecithin/sphingomyelin ratio (amniotic fluid)	LS	66749
Legionella pneumophila — serogroup 1 — microbial antibody testing	LP1	69384
Legionella pneumophila — serogroup 2 — microbial antibody testing	LP2	69384
Leishmaniasis — microbial antibody testing	LEI	69384
Leptospira — microbial antibody testing	LEP	69384
Leucocyte count	WCC	65070
Leucocyte count — 3 surface markers — blood, CSF, serous fluid	LMH3	71139
Leucocyte count — 3 surface markers — tissue	LMT3	71141
Leucocyte count — 6 surface markers — blood, CSF, serous fluid and tissue(s)	LMHT	71145
Leucocyte count — 6 surface markers — blood, CSF, serous fluid or tissue	LM6	71143
Leucocyte count — CD34 surface marker only — blood	LMCD34	71146
Lignocaine	LIGN	66800
Lip — cytology on specimens from	SMCY	73043
Lipase	LIP	66500
Lipid studies	FATS	66500
Lipoprotein subclasses — electrophoresis	LEPG	66539
Listeria — microbial antibody testing	LIS	69384
Lithium	LI	66800
Liver function tests	LFT	66515
Liver/kidney microsomes — tissue antigens — antibodies	LKA	71119
Lupus anticoagulant	LUPA	65132–37, 65142
Luteinizing hormone	LH	66695
Lymphocyte — tissue antigens — antibodies	ALY	71109
Lymphocytes — functional tests — 1 test	LF1	71127
Lymphocytes — functional tests — 2 tests	LF2	71129
Lymphocytes — functional tests — 3 tests	LF3	71131
Magnesium	MG	66500
Mammary serum antigen	MSA	66650
Manganese	MN	66669–70
Mantoux test	MANT	73811
Measles — microbial antibody testing	MEA	69384
Mercury	HG	66672–73
Metabolic bone disease	CBMB	66776
Metanephrines	MNEP	66779
Methadone	MTDN	66812
Methaemalbumin detection (Schumm’s test)	SCHM	65117
Methotrexate	MTTA	66812
Methsuximide	MSUX	66812
Methylphenobarbitone	MPBT	66812
Metronidazole	MRDZ	66812
Mexiletine (Mexitil)	MEX	66812
Mianserin	MIAS	66812
Microalbumin	MALB	66560
Microbial antibody testing — actinomycetes	ACT	69384
Microbial antibody testing — adenovirus	ADE	69384
Microbial antibody testing — aspergillus	ASP	69384
Microbial antibody testing — avian precipitins (bird fancier’s disease)	APP	69384
Microbial antibody testing — Blastomyces	BLM	69384
Microbial antibody testing — Bordetella pertussis	BOR	69384
Microbial antibody testing — Borrelia burgdorferi	BOB	69384
Microbial antibody testing — Brucella	BRU	69384
Microbial antibody testing — Campylobacter jejuni	CAM	69384
Microbial antibody testing — Candida	CAN	69384
Microbial antibody testing — Chlamydia	CHL	69384
Microbial antibody testing — Coccidioides	CCC	69384
Microbial antibody testing — Coxsackie B1-6	COX	69384
Microbial antibody testing — cryptococcus	CRY	69384
Microbial antibody testing — cytomegalovirus	CMV	69384
Microbial antibody testing — cytomegalovirus serology in pregnancy	CMVP	69384
Microbial antibody testing — dengue	DEN	69384
Microbial antibody testing — diphtheria	DIP	69384
Microbial antibody testing — echinococcus	ECC	69384
Microbial antibody testing — echo-coxsackie group	ECH	69384
Microbial antibody testing — Entamoeba histolytica	AMO	69384
Microbial antibody testing — Epstein Barr virus	EBV	69472–74
Microbial antibody testing — fluorescent treponemal antibody — absorption test (FTA-ABS)	FTA	69384
Microbial antibody testing — Haemophilus influenzae	HUS	69384
Microbial antibody testing — herpes simplex virus	HPA	69384
Microbial antibody testing — Histoplasma	HIP	69384
Microbial antibody testing — hydatid	HYD	69384
Microbial antibody testing — infectious mononucleosis	IM	69384
Microbial antibody testing — influenza A	FLA	69384
Microbial antibody testing — influenza B	FLB	69384
Microbial antibody testing — Legionella pneumophila — serogroup 1	LP1	69384
Microbial antibody testing — Legionella pneumophila — serogroup 2	LP2	69384
Microbial antibody testing — leishmaniasis	LEI	69384
Microbial antibody testing — Leptospira	LEP	69384
Microbial antibody testing — Listeria	LIS	69384
Microbial antibody testing — measles	MEA	69384
Microbial antibody testing — Micropolyspora faeni	MIC	69384
Microbial antibody testing — mumps	MUM	69384
Microbial antibody testing — Murray Valley encephalitis	MVE	69384
Microbial antibody testing — Mycoplasma pneumoniae	MYC	69384
Microbial antibody testing — Neisseria meningitidis	MEN	69384
Microbial antibody testing — Newcastle disease	NCD	69384
Microbial antibody testing — parainfluenza 1	PF1	69384
Microbial antibody testing — parainfluenza 2	PF2	69384
Microbial antibody testing — parainfluenza 3	PF3	69384
Microbial antibody testing — paratyphi	PTY	69384
Microbial antibody testing — pertussis	PER	69384
Microbial antibody testing — poliomyelitis	PLO	69384
Microbial antibody testing — Proteus OX 19	POX	69384
Microbial antibody testing — Proteus OXK	POK	69384
Microbial antibody testing — Q fever	QFF	69384
Microbial antibody testing — rapid plasma reagin test	RPR	69384
Microbial antibody testing — respiratory syncytial virus	RSV	69384
Microbial antibody testing — Ross River virus	RRV	69384
Microbial antibody testing — rubella	RUB	69384
Microbial antibody testing — Salmonella typhi (H)	SAH	69384
Microbial antibody testing — Salmonella typhi (O)	SAO	69384
Microbial antibody testing — Schistosoma	STO	69384
Microbial antibody testing — streptococcal serology — anti-DNASE B titre	ADNB	69384
Microbial antibody testing — streptococcal serology — anti-streptolysin O titre	ASOT	69384
Microbial antibody testing — Streptococcus pneumoniae	PCC	69384
Microbial antibody testing — tetanus	TET	69384
Microbial antibody testing — Thermoactinomyces vulgaris	THE	69384
Microbial antibody testing — thermopolyspora	TPS	69384
Microbial antibody testing — Toxocara	TOC	69384
Microbial antibody testing — toxoplasma	TOX	69384
Microbial antibody testing — TPHA (Treponema pallidum haemagglutination test)	TPHA	69384
Microbial antibody testing — Treponema pallidum haemagglutination test	TPHA	69384
Microbial antibody testing — trichinosis	TOS	69384
Microbial antibody testing — typhus, Weil-Felix	TYP	69384
Microbial antibody testing — Varicella zoster	VCZ	69384
Microbial antibody testing — VDRL (Venereal Disease Research Laboratory)	VDRL	69384
Microbial antibody testing — Yersinia enterocolitica	YER	69384
Microbial antigen testing — Chlamydia	MCCH	69315, 69369
Microbial antigen testing — Clostridium difficile	CLDT	69363
Microbial antigen testing — group B streptococcus	STB	69372
Microbial antigen testing — Haemophilus influenzae	HI	69372
Microbial antigen testing — herpes simplex virus	HSV	69375
Microbial antigen testing — Neisseria gonorrhoeae	GON	69372
Microbial antigen testing — Neisseria meningitidis	NMG	69372
Microbial antigen testing — respiratory syncytial virus	RSVN	69372
Microbial antigen testing — Streptococcus pneumoniae	SPN	69372
Microbial antigen testing — Varicella zoster	VCZN	69375
Micropolyspora faeni	MIC	69384
Microscopic examination of — faeces for parasites	OCP	69336–39
Microscopic examination of — wet film material other than blood	MWFM	69300
Microscopy and culture of — material from nose, throat, eye or ear	MCSW	69303
Microscopy and culture of — material from skin	MCSK	69309
Microscopy and culture of — postoperative wounds, aspirates of body cavities	MCPO	69321
Microscopy and culture of — superficial sites	MCSS	69306
Microscopy and culture of — urethra, vagina, cervix or rectum	MCGR	69312
Microscopy and culture of — specimens of sputum	MCSP	69318
Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria — 1 specimen	AFB1	69324
Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria — 2 specimens	AFB2	69327
Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria — 3 specimens	AFB3	69330
Microscopy and culture to detect pathogenic micro-organisms including chlamydia	MCCH	69315
Microscopy, culture, identification and sensitivity of urine	UMCS	69333
Mitochondria — tissue antigens — antibodies	MA	71119
Mouth — cytology on specimens from	SMCY	73043
Mumps — microbial antibody testing	MUM	69384
Murray Valley encephalitis — microbial antibody testing	MVE	69384
Mycobacteria microscopy and culture of sputum — 1 specimen	AFB 1	69324
Mycobacteria microscopy and culture of sputum — 2 specimens	AFB 2	69327
Mycobacteria microscopy and culture of sputum — 3 specimens	AFB 3	69333
Mycoplasma pneumoniae — microbial antibody testing	MYC	69384
Myoglobin	MYOG	66518
N-acetyl procainamide	NAPC	66812
Neisseria gonorrhoeae by NAA techniques and chlamydia by any method	CHGO	69370
Neisseria gonorrhoeae — microbial antigen testing	GON	69372
Neisseria meningitidis — antigens	NMG	69372
Neisseria meningitidis — microbial antibody testing	MEN	69384
Neisseria meningitidis — microbial antigen testing	NMG	69372
Netilmicin	66800
Neural tube defects and Down’s syndrome	NTDD	66750, 66751
Neuron — tissue antigens — antibodies	ANE	71109
Neutrophil cytoplasm — tissue antigens — antibodies	ANCA	71109
Neutrophil functions	NFT	71135
Newcastle disease — microbial antibody testing	NCD	69384
Nickel	NI	66672–73
Nipple discharge — cytology on specimens from	SMCY	73043
Nitrazepam	NITR	66812
Nordothiepin	NDIP	66812
Norfluoxetine	NFLE	66812
Nortriptyline	NORT	66812
Nose — cytology on specimens from	SMCY	73043
Nose — microscopy and culture of material from	MCSW	69303
Nuclear antigens — detection of antibodies to	ANA	71097
Oestradiol	E2	66695
Oestriol	E3	66750, 66751
Oestrone	E1	66695
Oligoclonal proteins	OGP	71062
Op/biopsy specimens — microscopy and culture of material from	MCPO	69321
Oral glucose challenge test — gestational diabetes	OGCT	66545
Oral glucose tolerance test — gestational diabetes	GTTP	66542
Osmolality, serum or urine	OSML	66563
Ovary — tissue antigens — antibodies	AOV	71109
Oxalate	OXAL	66752
Oxazepam	OXAZ	66812
PAA (phenyl acetic acid)	PAA	66779
Palmitic acid in amniotic fluid	PALM	66749
Pap smear	CCR	73053
Papanicolaou test	CCR	73053
Paracetamol	PARA	66800
Parainfluenza 1 — microbial antibody testing	PF1	69384
Parainfluenza 2 — microbial antibody testing	PF2	69384
Parainfluenza 3 — microbial antibody testing	PF3	69384
Paraprotein characterisation — by electrophoresis and immunoelectrophoresis or immunofixation or isoelectric focussing	PPRO	71059
Paraprotein characterisation — on concurrently collected serum or urine	PPSU	71060
Paraprotein quantitation — by electrophoresis	EPPI	71057
Paraquat	PARQ	66812
Parasites — microscopic examination of faeces	OCP	69336–39
Parathyroid hormone (PTH)	PTH	66695
Parathyroid — tissue antigens — antibodies	PTHA	71109
Paratyphi — microbial antibody testing	PTY	69384
Partial thromboplastin time	PTT	65120
Patient episode initiation fees	PEI	73901–15
Pentagastrin	PSTR	66689
Pentobarbitone	PENT	66812
Perhexiline	PHEX	66812
Pertussis — microbial antibody testing	PER	69384
Phenobarbitone	PHBA	66800
Phensuximide	PHEN	66812
Phenylacetic acid	PAA	66779
Phenytoin	PHEY	66800
Phosphate	PHOS	66500
Phosphatidylglycerol	PTGL	66749
Plasminogen	PLAS	65139
Platelet — aggregation	PLTG	65144
Platelet — count	PLTC	65070
Platelet — tissue antigens — antibodies	APA	71109
PM-Sc1 — tissue antigens — antibodies	PM1	71119
Poliomyelitis — microbial antibody testing	PLO	69384
Porphobilinogen in urine	UPG	66782
Porphyrins — quantitative test, 1 or more fractions	PR	66785
Porphyrins in urine — qualitative test	UPR	66782
Potassium	K	66500
Prealbumin	PALB	66632
Prednisolone	PRED	66812
Pregnancy serology — 1 test	MSP1	69405
Pregnancy serology — 2 tests	MSP2	69408
Pregnancy serology — 3 tests	MSP3	69411
Pregnancy serology — 4 tests	MSP4	69413
Pregnancy testing	73806
Pregnancy testing — diagnosis of Down’s syndrome and neural tube defect	NTDD	66750, 66751
Pregnancy testing — HCG detection	HCG	73527, 73529
Pregnancy testing — HCG quantitation	HCG	73529
Primidone	PRIM	66800
Procainamide	PCAM	66800
Progesterone	PROG	66695
Prolactin	PROL	66695
Propranolol	PPNO	66812
Prostate specific antigen	PSA	66655–59
Protein — C	PROC	65132–36, 65142, 65171
Protein — S	PROS	65132–36, 65142, 65171
Protein, quantitation of — alpha fetoprotein	AFP	66650–53, 66743, 66750, 66751
Protein, quantitation of — alpha-l-antitrypsin	AAT	66635
Protein, quantitation of — beta-2-microglobulin	BMIC	66629
Protein, quantitation of — caeruloplasmin	CPLS	66632
Protein, quantitation of — C-l esterase inhibitor	CEI	66644
Protein, quantitation of — classes or presence and amount of paraprotein by electrophoresis	EPPI	71057, 71058
Protein, quantitation of — ferritin (see also Iron studies)	FERR	66593
Protein, quantitation of — for Down’s syndrome/neural tube defect testing	NTDD	66750, 66751
Protein, quantitation of — haptoglobins	HGLB	66632
Protein, quantitation of — microalbumin	MALB	66560
Protein, total — quantitation of	PROT	66500
Proteus OX 19 — microbial antibody testing	POX	69384
Proteus OXK — microbial antibody testing	POK	69384
Prothrombin gene mutation	PGM	65168, 65174
Prothrombin time	PT	65120
Pyruvate	PVTE	66500
Q fever — microbial antibody testing	QFF	69384
Quinalbarbitone	QUIB	66812
Quinidine	QUIN	66800
Quinine	QNN	66812
Rapid plasma reagin test — microbial antibody testing	RPR	69384
RAST	RAST	71079
Rectum — microscopy and culture of material from	MCGR	69312
Rectum — microscopy, culture and Chlamydia of material from	MCCH	69315
Red blood cells — Kleihauer	KLEI	65162
Red cell folate and serum B12	B12F	66602
Red cell folate and serum B12 and serum folate if required	B12F	66602
Red cell folate and serum folate	RCF	66599
Red cell porphyrins — qualitative test	RCP	66782
Referred specimen fee	73921
Renin	REN	66695
Reptilase test	REPT	65120
Respiratory syncytial virus — microbial antibody testing	RSV	69384
Respiratory syncytial virus — microbial antigen testing	RSVN	69372
Reticulin — tissue antigens — antibodies	RCA	71119
Reticulocyte count	RETC	65072
Rheumatoid factor	RF	71106
Rheumatoid factor — quantitation	RFQ	71106
Ross River virus — microbial antibody testing	RRV	69384
RSV (respiratory syncytial virus) — microbial antibody testing	RSV	69384
RSV (respiratory syncytial virus) — microbial antigen testing	RSVN	69372
Rubella — serology	RUB	69384
Salicylate (aspirin)	SALI	66800
Salivary gland — tissue antigens — antibodies	ASG	71109
Salmonella typhi (H) — microbial antibody testing	SAH	69384
Salmonella typhi (O) — microbial antibody testing	SAO	69384
Schistosoma — microbial antibody testing	STO	69384
Scl-70 — tissue antigens — antibodies	SCL	71119
Secretin	SSGR	66689
Selenium	SE	66669–70
Semen examination	SEE	73523
Semen examination — for spermatozoa (post vasectomy)	SES	73521
Serology — in pregnancy (see Pregnancy serology)
Serotonin	5HT	66779
Serum — Bl2	B12	66599
Serum — folate (with Bl2 red cell folate)	B12F	66602
Serum — folate (with Bl2)	B12	66599
Sex hormone binding globulin	SHBG	66695
Skeletal muscle — tissue antigens — antibodies	SLA	71109
Skin — cytology	SMCY	73043
Skin — microscopy and culture of material from	MCSS	69306
Skin — microscopy, culture and Chlamydia of material from	MCSK	69309
Skin basement membrane — tissue antigens — antibodies	SKA	71109
Smooth muscle — tissue antigens — antibodies	SMA	71119
Snake venom	HISS	66623
Sodium	NA	66500
Solid tissue or tissues — chemical assays	ENZS	66683
Solid tissue or tissues — cytology of fine needle aspiration	FNCY	73049
Solid tissue or tissues — cytology of fine needle aspiration by, or in presence of pathologist	FNCP	73051
Somatomedin	SOMA	66695
Sotalol	SALL	66812
Specific IgE or IgG antibodies	RAST	71079
Specimen referred fee	73921
Sperm antibodies	SAB	73525
Sperm antibodies — penetrating ability	SPA	73525
Sputum — cytology (1 specimen)	BFCY	73045
Sputum — cytology (3 specimens)	SPCY	73047
Sputum — for mycobacteria — 1 specimen	AFB1	69324
Sputum — for mycobacteria — 2 specimens	AFB2	69327
Sputum — for mycobacteria — 3 specimens	AFB3	69330
Sputum — microscopy and culture of specimens	MCSP	69318
Stelazine	STEL	66812
Steroid fraction or fractions in urine	USF	66695
Streptococcal serology — anti-DNASE B titre — microbial antibody testing	ADNB	69384
Streptococcal serology — anti-streptolysin O titre — microbial antibody testing	ASOT	69384
Streptococcus — Group B	STB	69372
Streptococcus pneumoniae — CSF antigens	SPN	69372
Streptococcus pneumoniae — microbial antibody testing	PCC	69384
Streptococcus pneumoniae — microbial antigen testing	SPN	69372
Strontium	SR	66672–73
Stypven test	STYP	65120
Sugar water test	SWT	65075
Sulthiame (Ospolot)	SUL	66812
Supplementary testing for Hepatitis C antibodies	HCST	69441
Synacthen stimulation test	SYNS	66689
Syphilis serology	STS	69387
Testosterone	TES	66695
Tetanus — microbial antibody testing	TET	69384
Thalassaemia studies	TS	65078
Theophylline	THEO	66800
Thermoactinomyces vulgaris — microbial antibody testing	THE	69384
Thermopolyspora — microbial antibody testing	TPS	69384
Thiopentone	TOPO	66812
Thioridazine	THIO	66812
Throat — microscopy and culture of material from	MCSW	69303
Thrombin time	TT	65120
Thrombophilia testing (see individual thrombophilia tests)
Thyroglobulin	TGL	66650
Thyroglobulin — tissue antigens — antibodies	ATG	71109
Thyroid function tests (including TSH)	TFT	66719
Thyroid microsome — tissue antigens — antibodies	TMA	71109
Thyroid stimulating hormone (if requested on its own, or as a preliminary test to thyroid function testing)	TSH	66716
Thyroid stimulating hormone (if requested with other hormones referred to in item 66695)	TSH	66722–34
Thyrotrophin releasing hormone test	TRH	66689
Tissue transglutaminase antibodies	TTG	71163
Tobramycin	66800
Total protein	PROT	66500
Toxocara — microbial antibody testing	TOC	69384
Toxoplasma — microbial antibody testing	TOX	69384
TPHA (Treponema pallidum haemagglutination test) — microbial antibody testing	TPHA	69384
Treponema pallidum haemagglutination test — microbial antibody testing	TPHA	69384
Trichinosis — microbial antibody testing	TOS	69384
Triglycerides	TRIG	66500
Trimipramine	TRIM	66812
Troponin	TROP	66518
Tryptic activity in faeces	TAF	66677
TSH receptor antibody test — tissue antigens — antibodies	TSHA	71109
Tuberculosis	MANT	73811
Tumour markers — CA-15.3 antigen	CA15	66650
Tumour markers — CA-19.9 antigen	CA19	66650
Tumour markers — CA-125 antigen	C125	66650
Tumour markers — carcinoembryonic antigen	CEA	66650
Tumour markers — mammary serum antigen	MSA	66650
Tumour markers — prostate specific antigen	PSA	66656
Tumour markers — prostatic acid phosphatase — 1 or more fractions	ACP	66656
Tumour markers — thyroglobulin	TGL	66650
Typhus, Weil-Felix — microbial antibody testing	TYP	69384
Urate	URAT	66500
Urea	U	66500
Urea, electrolytes, creatinine	U&E	66515
Urethra — microscopy and culture of material from	MCGR	69312
Urethra — microscopy, culture and Chlamydia of material from	MCCH	69315
Urine — acidification test	UAT	66587
Urine — catalase test	UCAT	73805
Urine — cystine (cysteine)	UCYS	66782
Urine — cytology — on 1 specimen	BFCY	73045
Urine — cytology — on 3 specimens	SPCY	73047
Urine — haemoglobin	UHB	66782
Urine — microscopy, culture, identification and sensitivity	UMCS	69333
Urine — porphobilinogen	UPG	66782
Urine — porphyrins — qualitative test	UPR	66782
Urine — steroid fraction or fractions	USF	66695
Urine — urobilinogen	UUB	66782
Vagina — microscopy and culture of material from	MCGR	69312
Vagina — microscopy, culture and Chlamydia of material from	MCCH	69315
Vagina — cytology on specimens from	CVO	73057
Valproate (Epilim)	VALP	66800
Vancomycin	VAN	66800
Varicella zoster — microbial antibody testing	VCZ	69384
Varicella zoster — microbial antigen testing	VCZN	69372
Vasoactive intestinal peptide	VIP	66695
Vasopressin	ADH	66695
VDRL (Venereal Disease Research Laboratory) — microbial antibody testing	VDRL	69384
Viscosity of blood or plasma	VISC	65060
Vitamins — B12	B12	66599
Vitamins — D	VITD	66608
Vitamins — folate	RCF	66599
Vitamins — quantitation of A, B1, B2, B3, B6, C or E	VIT	66605
VMA (see HMMA)
Von Willebrand’s factor	VWF	65150
Von Willebrand’s factor antigen	VWA	65150
Warfarin	WFR	66812
Yersinia enterocolitica — microbial antibody testing	YER	69384
Zinc	ZN	66667–70

Part 5 Complexity levels for histopathology items

Specimen type	Complexity level
Adrenal resection, neoplasm	5
Adrenal resection, not neoplasm	4
Anus, all specimens not otherwise specified	3
Anus, neoplasm, biopsy	4
Anus, neoplasm, radical resection	6
Appendix	3
Artery, all specimens not otherwise specified	3
Artery, biopsy	4
Bartholin’s gland — cyst	3
Bile duct, resection — all specimens	6
Bone, biopsy, curettings or fragments — lesion	5
Bone, biopsy or curettings quantitation — metabolic disease	6
Bone, femoral head	4
Bone, resection, neoplasm — all sites and types	6
Bone marrow, biopsy	4
Bone — all specimens not otherwise specified	4
Brain neoplasm, resection — cerebello-pontine angle	4
Brain or meninges, biopsy — all lesions	5
Brain or meninges, not neoplasm — temporal lobe	6
Brain or meninges, resection — neoplasm (intracranial)	5
Brain or meninges, resection — not neoplasm	4
Branchial cleft, cyst	4
Breast, excision biopsy, guidewire localisation — non-palpable lesion	6
Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease — all specimen types	6
Breast, incision biopsy or needle biopsy, malignant neoplasm — all specimen types	4
Breast, microdochectomy	6
Breast tissue — all specimens not otherwise specified	4
Bronchus, biopsy	4
Carotid body — neoplasm	5
Cholesteatoma	3
Digits, amputation — not traumatic	4
Digits, amputation — traumatic	2
Ear, middle and inner — not cholesteatoma	4
Endocrine neoplasm — not otherwise specified	5
Extremity, amputation or disarticulation — neoplasm	6
Extremity, amputation — not otherwise specified	4
Eye, conjunctiva — biopsy or pterygium	3
Eye, cornea	4
Eye, enucleation or exenteration — all lesions	6
Eye — not otherwise specified	4
Fallopian tube, biopsy	4
Fallopian tube, ectopic pregnancy	4
Fallopian tube, sterilization	2
Fetus with dissection	6
Foreskin — new born	2
Foreskin — not new born	3
Gallbladder	3
Gallbladder and porta hepatis-radical resection	6
Ganglion cyst, all sites	3
Gum or oral mucosa, biopsy	4
Heart valve	4
Heart — not otherwise specified	5
Hernia sac	2
Hydrocele sac	2
Jaw, upper or lower, including bone — radical resection for neoplasm	6
Joint and periarticular tissue, without bone — all specimens	3
Joint tissue, including bone — all specimens	4
Kidney, biopsy including transplant	5
Kidney, nephrectomy transplant	5
Kidney, partial or total nephrectomy or nephroureterectomy — neoplasm	6
Kidney, partial or total nephrectomy — not neoplasm	4
Large bowel (including rectum), biopsy — all sites	4
Large bowel (including rectum), biopsy, for confirmation or exclusion of Hirschsprung’s Disease	5
Large bowel, colostomy — stoma	3
Large bowel (including rectum), polyp	4
Large bowel, segmental resection — colon, not neoplasm	5
Large bowel (including rectum), segmental resection, neoplasm	6
Larynx, biopsy	4
Larynx, partial or total resection	5
Larynx, resection with nodes or pharynx or both	6
Lip biopsy — all specimens not mentioned	3
Lip wedge resection or local excision with orientation	4
Liver, hydatid cyst or resection for trauma	4
Liver, total or subtotal hepatectomy — neoplasm	6
Liver — all specimens not otherwise specified	5
Lung, needle or transbronchial biopsy	4
Lung, resection — neoplasm	6
Lung, wedge biopsy	5
Lung segment, lobar or total resection	6
Lymph node, biopsy — all sites	4
Lymph node, biopsy, for lymphoma or lymphoproliferative disorder	5
Lymph nodes, regional resection — all sites	5
Mediastinum mass	5
Muscle, biopsy	6
Nasopharynx or oropharynx, biopsy	4
Nerve, biopsy neuropathy	5
Nerve, neurectomy or removal of neoplasm	4
Nerve — not otherwise specified	3
Nose, mucosal biopsy	4
Nose or sinuses, polyps	3
Odontogenic neoplasm	5
Odontogenic or dental cyst	4
Oesophagus, biopsy	4
Oesophagus, diverticulum	3
Oesophagus, partial or total resection	6
Omentum, biopsy	4
Ovary with or without tube — neoplasm	5
Ovary with or without tube — not neoplasm	4
Pancreas, biopsy	5
Pancreas, cyst	4
Pancreas, subtotal or total with or without splenectomy	6
Parathyroid gland(s)	4
Penisectomy with node dissection	5
Penisectomy — simple	4
Peritoneum, biopsy	4
Pituitary neoplasm	4
Placenta — not third trimester	4
Placenta — third trimester, abnormal pregnancy or delivery	4
Pleura or pericardium, biopsy or tissue	4
Products of conception, spontaneous or missed abortion	4
Products of conception, termination of pregnancy	3
Prostate, radical resection	6
Prostate — all types of specimen not otherwise specified	4
Retroperitoneum, neoplasm	5
Salivary gland, Mucocele	3
Salivary gland, neoplasm — all sites	5
Salivary gland — all specimens not otherwise specified	4
Sinus, paranasal, biopsy	4
Sinus, paranasal, resection — neoplasm	6
Skin, biopsy — blistering skin diseases	4
Skin, biopsy — inflammatory dermatosis	4
Skin, biopsy — investigation of alopecia where serial horizontal sections are taken, except for male pattern baldness	5
Skin, biopsy — investigation of lymphoproliferative disorder	5
Skin, eyelid, wedge resection	4
Skin, local resection — orientation	4
Skin, resection of malignant melanoma or melanoma in situ	5
Skin — all specimens not otherwise specified including all neoplasms and cysts	3
Small bowel — biopsy, all sites	4
Small bowel, diverticulum	3
Small bowel, resection — neoplasm	6
Small bowel — all specimens not otherwise specified	5
Soft tissue, infiltrative lesion — extensive resections at least 5 cm in maximal dimension	6
Soft tissue, lipoma and variants	3
Soft tissue, neoplasm, not lipoma — all specimens	5
Soft tissue — not otherwise specified	4
Spleen	5
Stomach, endoscopic biopsy or endoscopic polypectomy	4
Stomach, resection, neoplasm — all specimens	6
Stomach — all specimens not otherwise specified	4
Tendon or tendon sheath, giant cell neoplasm	4
Tendon or tendon sheath — not otherwise specified	3
Testis, biopsy	5
Testis and adjacent structures, castration	2
Testis and adjacent structures, neoplasm with or without nodes	5
Testis and adjacent structures, vas deferens sterilization	2
Testis and adjacent structures — not otherwise specified	3
Thymus — not otherwise specified	5
Thyroglossal duct — all lesions	4
Thyroid — all specimens	5
Tissue or organ not otherwise specified, abscess	3
Tissue or organ not otherwise specified, haematoma	3
Tissue or organ not otherwise specified, malignant neoplasm with regional nodes	6
Tissue or organ not otherwise specified, neoplasm local	4
Tissue or organ not otherwise specified, pilonidal cyst or sinus	3
Tissue or organ not otherwise specified, thrombus or embolus	3
Tissue or organ not otherwise specified, veins varicosity	3
Tissue or organ — all specimens not otherwise specified	3
Tongue, biopsy	4
Tongue or tonsil, neoplasm local	5
Tongue or tonsil, neoplasm with nodes	6
Tonsil, biopsy — excluding resection of whole organ	4
Tonsil or adenoids or both	2
Trachea, biopsy	4
Ureter, biopsy	4
Ureter, resection	5
Urethra, biopsy	4
Urethra, resection	5
Urinary bladder, partial or total with or without prostatectomy	6
Urinary bladder, transurethral resection of neoplasm	5
Urinary bladder — all specimens not otherwise specified	4
Uterus, cervix, curettings or biopsy	4
Uterus, cervix cone, biopsy (including LEEP or LLETZ biopsy)	5
Uterus, endocervix, polyp	3
Uterus, endometrium, polyp	3
Uterus, with or without adnexa, malignant neoplasm — all specimen types not otherwise specified	6
Uterus with or without adnexa, neoplasm, Wertheim’s or pelvic clearance	6
Uterus and/or cervix — all specimens not otherwise specified	4
Vagina, biopsy	4
Vagina, radical resection	6
Vaginal mucosa, incidental	3
Vulva or labia, biopsy	4
Vulval, subtotal or total with or without nodes	6

Notes to the Health Insurance (Pathology Services Table) Regulations 2004

Note 1

The Health Insurance (Pathology Services Table) Regulations 2004 (in force under the Health Insurance Act 1973) as shown in this compilation comprise Statutory Rules 2004 No. 309 amended as indicated in the Tables below.

Under the Legislative Instruments Act 2003, which came into force on 1 January 2005, it is a requirement for all non-exempt legislative instruments to be registered on the Federal Register of Legislative Instruments. From 1 January 2005 the Statutory Rules series ceased to exist and was replaced with Select Legislative Instruments (SLI series). Numbering conventions remain the same, ie Year and Number.

Table of Instruments

Year and number	Date of notification in *Gazette* or FRLI registration	Date of commencement	Application, saving or transitional provisions
2004 No. 309	29 Oct 2004	1 Nov 2004
2005 No. 67	27 Apr 2005 (see F2005L00936)	1 May 2005	—

Table of Amendments

ad. = added or inserted am. = amended rep. = repealed rs. = repealed and substituted
Provision affected	How affected
Schedule 1
Part 2
Part 2......................................	am. 2005 No. 67
Part 3
Part 3......................................	am. 2005 No. 67